Company Pipeline Database

OVER 1000 indications in Phase 2,3 or NDA development. Updated daily, includes PRs and live share price. AMEX/NASDAQ/NYSE. Generally no OTC.

NOTE:

SMALL/MID cap companies: Pipelines are shown in full from Phase 2 development onwards.

LARGE cap companies are generally NOT featured in the database.

TickerPriceDrugIndicationStageLinkClinical Trial IDUpdated
ALIOF
106.96Selexipag - UptraviPulmonary arterial hypertension (PAH)PDUFAAnnounced Dec 23 2014 that NDA filing has been submitted. Estimated PDUFA Dec 23 201501/26/2015
ALKS
69.81Three-Month INVEGA SUSTENNA (paliperidone palmitate)SchizophreniaPDUFANDA filed approx Nov 24 2014. Priority Review. Estimated PDUFA July 24 2015. 01/26/2015
AMGN
159.81EvolocumabLDL Cholesterol-Lowering Medication PDUFAPDUFA Aug. 27, 201501/26/2015
AMGN
159.81Talimogene laherparepvecMelanomaPDUFAPDUFA July 28 201501/26/2015
BAYRY
143.37BAY 81-8973Hemophilia APDUFABLA filed about Dec 17 2014. Estimated PDUFA Dec 17 201501/26/2015
BAX
71.43BAX111Von Willebrand DiseasePDUFABLA filed about Dec 22 2014. Estimated PDFUA Dec 22 2015 01/26/2015
BAX
71.43BAX 855Hemophilia APDUFABLA filed about Dec 1 2014. Estimated PDUFA Dec 1 201501/26/2015
EBS
28.39Anthrax Immune Globulin Intravenous (Human) [AIGIV] AnthraxPDUFA BLA filed early August 2014. Estimated PDUFA Aug 7 201501/26/2015
EBS
28.39BioThrax Anthrax Vaccine AdsorbedPDUFA sBLA PDUFA date estimated May 9 201501/26/2015
ESALY
43.74FycompaPrimary generalized tonic-clonic seizures (PGTC)PDUFAsNDA filed Aug 19 2014. Estimated PDUFA Aug 19 201501/26/2015
ESALY
43.74Lenvatinib mesylate (lenvatinib)Progressive radioiodine-refractory differentiated thyroid cancerPDUFAPDUFA date under priority review of April 14, 201501/26/2015
GEVA
118.89Sebelipase alfa (SBC-102)Late onset lysosomal acid lipase deficiency (LAL Deficiency)PDUFA BLA rolling submission completed Dec 2014. Estimated PDUFA Dec 2 201501/26/2015
GILD
105.54Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide HIVPDUFANDA filed approx Nov 6 2014. Estimated PDUFA Nov 6 201501/26/2015
JNJ
102.20YONDELISAdvanced soft tissue sarcoma (STS)PDUFA NDA filed approx Nov 24 2014. Estimated PDUFA Nov 24 201501/26/2015
JNJ
102.20Three-Month INVEGA SUSTENNA (paliperidone palmitate)SchizophreniaPDUFANDA filed approx Nov 24 2014. Priority Review. Estimated PDUFA July 24 2015. 01/26/2015
OPK
10.84Neurokinin-1 (“NK-1”) - Rolapitant (partnered with TSRO)Prevention of chemotherapy induced nausea and vomiting, or CINV PDUFANDA filed early Sept 2014. Estimated PDUFA Sept 8 201501/26/2015
PFE
32.45PalbociclibFirst-Line Therapy in Combination with Letrozole for ER+, HER2- Advanced Breast CancerPDUFAPDUFA date under priority review of April 13 201501/26/2015
PTX
8.68TREXIMETAdolescent migraine patientsPDUFAsNDA filed Nov 14 2014. Granted priority review. Estimated PDUFA July 14 201401/26/2015
SNY
46.88PraluentHypercholesterolemiaPDUFAPDUFA priority review date July 24 201501/26/2015
THRX
11.78BREO ELLIPTAAsthmaPDUFAsNDA PDUFA April 30 2014.01/26/2015
TSRO
40.80RolapitantPrevention of chemotherapy induced nausea and vomiting, or CINV in HEC patientsPDUFANDA filed early Sept 2014. Estimated PDUFA Sept 8 201501/26/2015
VRTX
125.57Lumacaftor and ivacaftorCystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation PDUFAPDUFA date July 5 2015 for the combination of lumacaftor and ivacaftor in people with CF ages 12 and older who have two copies of the F508del mutation - priority review01/26/2015
VRTX
125.57Vacaftor Children ages 2 to 5 with cystic cystic fibrosis who have the G551D or one of the eight additional gating mutationsPDUFAPDUFA March 17 201501/26/2015
KYTH
35.28ATX-101 Reduction of Localized Subcutaneous Fat in the Submental AreaPDUFAPDUFA May 13 2015. Advisory Committee Meeting March 9 201501/25/2015
NPSP
45.64NatparaHypoparathyroidismApprovedApproved Jan 23 2015 01/25/2015
PGNX
6.14AzedraPheochromocytomaPhase 2bPivotal Phase 2 trial resumed January 2015 following suspension of trial in 2010 due to lack of funding01/25/2015
ALXA
2.10AZ-002Acute repetitive seizuresPhase 2Phase 2 initiated late Jan 201401/23/2015
CYTR
2.77AldoxorubicinCancer - soft tissue sarcomas first linePhase 2bOverall survival data - secondary endpoint released Jan 2015 - HR 0.73 CI 0.44-1.20 - OS 16.0 months vs 14.4 (p=0.21) - not statistically significant01/23/2015
MDVN
106.27MDV3100 cf Bicalutamide TERRAIN trial Cancer - prostate enrolling only metastaticPhase 2Met primary endpoint late Jan 2015. HR 0.44, Median PFS 15.7 months for enzalutamide compared to 5.8 months for bicalutamide01/23/2015
OCUL
26.35OTX-DPDry Eye DiseasePhase 2Phase 2 enrolment commenced mid Jan 201501/22/2015
CYTR
2.77Aldoxorubicin with doxorubicinCancer - soft tissue sarcomas refractoryPhase 3Phase 3 initiated March 2014 under SPA, expect to complete trial enrollment in 2H 2015. Unblind data by mid-2016 01/21/2015
CASI
1.68ENMD-2076Cancer - fibrolamellar carcinoma (FLC).Phase 2Plans to initiate a Phase 2 trial in 201501/19/2015
CASI
1.68ENMD-2076 Cancer - Advanced/Metastatic Soft Tissue SarcomaPhase 2Phase 2 initiated Jan 2013. Enrolling as of Nov 201401/19/2015
CASI
1.68ENMD-2076Cancer - triple-negative breast cancerPhase 2Phase 2 initiated Jul 2012. Enrolling as of Nov 201401/19/2015
OGXI
2.09Custirsen in combination with Jevtana (cabazitaxel)-AFFINITYCancer - castrate-resistant prostate second-linePhase 3Initiated 2nd Phase 3 trial Aug 2012. Enrolment completed Sept 2014. Data due late 2015 or early 201601/19/2015
CUR
3.12 NSI-566Amyotrophic lateral sclerosis (Lou Gehrig's)Phase 2Phase 2 data are due LATE 1Q or EARLY 2Q 2015 according to Jan 2015 presentation. 01/16/2015
TGTX
14.08TG-1101 and TGR-1202Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)Phase 3Phase 3 trials planned for 1H and 2H 201501/16/2015
TGTX
14.08TG-1101 and IMBRUVICA (GENUINE trial)Chronic Lymphocytic Leukemia (CLL) Phase 3Phase 3 open for enrolment as of mid Jan 201501/16/2015
TNXP
6.20TNX-102 SL PTSD - for the treatment of post-traumatic stress disorderPhase 2Phase 2 trial initiated mid Jan 201501/16/2015
BCRX
10.99BCX4161 - OPuS-2Hereditary angioedemaPhase 2bPhase 2b data due by end of 201501/15/2015
ETRM
1.15VBLOCObesityApprovedApproved Jan 14, 201501/15/2015
OPK
10.84CTAP101 Capsules - (Rayaldy)Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiencyNDANDA filng due 1Q 201501/15/2015
RGDO
1.06Cenicriviroc (CVC) - CENTAUR trialNon-alcoholic steatohepatitis (NASH)Phase 2bFollowing merger announcement with Tobira Therapeutics in mid-Jan 2015, Phase 2b NASH data are due in 2Q 201601/15/2015
ATRS
2.35VIBEX QuickShotTestosterone deficiencyPhase 3Phase 3 initiated July 2014. Final patient dosed Nov 2015. Top-line pharmacokinetic data due 2Q 201501/14/2015
CPRX
3.06Firdapse Lambert-Easton Myasthenic Syndrome (LEMS)Phase 3Phase 3 data due released Sept. Rolling NDA to be filed 1H 2015, to be completed 3Q 201501/14/2015
SRNE
9.97CynviloqCancerBioequivalence trialTop-line pharmacokinetic results from TRIBECA (TRIal establishing bioequivalence BE between Cynviloq and Albumin-bound paclitaxel) due in March 201501/14/2015
VTL
21.56ELAD (VTI-208)Alcohol-induced liver decompensation, or AILDPhase 3Phase 3 initiated 2013. Prelim data due 2Q 201501/14/2015
VTL
21.56ELAD (VTI-210)Severe acute alcoholic hepatitisPhase 3Phase 3 data due 201601/14/2015
VTL
21.56ELAD (VTI-212)Fulminant hepatic failure, or FHF, or surgery-induced acute liver failure, or SILFPhase 2/3Phase data due 201601/14/2015
ADMS
17.01ADS-5102Levodopa-Induced DyskinesiaPhase 3Phase 3 initiated June 2014. Further trial initiated Oct 2014. Enrolment to be completed in 2015. Data from first trial expected around the end of 2015. NDA planned for 2016.01/13/2015
AERI
29.92RhopressaGlaucomaPhase 3Phase 3 Rocket 1 trial data due mid-2Q 2015. Rocket 2 data due mid 201501/13/2015
ARIA
6.10Iclusig (ponatinib) Cancer - second line chronic-phase CML (CP-CML) Phase 3Phase 2 dose ranging trial to be initiated 2H 201501/13/2015
ARIA
6.10Iclusig (ponatinib)Cancer - third line chronic-phase CML (CP-CML)Phase 2Phase 2 dose ranging trial to be initiated mid 201501/13/2015
ARIA
6.10Brigatinib - ALTA trialAnaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC)Phase 2 pivotalExpect to complete enrolment 3Q 2015 and to file for approval in mid-2016.01/13/2015
ARNA
4.55RalinepagPulmonary Arterial HypertensionPhase 2Phase 2 initiated mid Jan 201501/13/2015
ARWR
6.43ARC-520 injection in combination with entecavir or tenofovirChronic HBVPhase 2bPartial clinical hold placed by FDA in early Jan 2015. Phase 2b trial to proceed with lower doses than initially proposed01/13/2015
ASPX
58.46SD-809Huntington's disease (HD)Phase 3Phase 3 topline released Dec 16 2014 met endpoints. NDA filing due by mid 201501/13/2015
CYTX
0.48ECCS-50SclerodermaPivotalPivotal trial to be initiated 201501/13/2015
FATE
4.85ProHema Adult hematologic malignanciesPhase 2Phase 2 data due mid-2015. 01/13/2015
HALO
13.87PEGPH20 Cancer - pancreaticPhase 2Clinical hold lifted June 2014.Patient enrolment recommenced July 2014. Enrolment due to be completed 2H 201501/13/2015
HALO
13.87PEGPH20 in Combination with docetaxelCancer - NSCLCPhase 1bComplete enrolment 3Q 201501/13/2015
HZNP
16.21ACTIMMUNEFriedreich's Ataxia (FA)Phase 3Phase 3 to be initiated 2Q 201501/13/2015
ICPT
165.76Obeticholic acid (OCA)Adult nonalcoholic steatohepatitis (NASH) patients. Phase 2FLINT trial stopped early due to strong efficacy Jan 2014. Phase 3 to be initiated 1H 201501/13/2015
ICPT
165.76Obeticholic acid (OCA)Primary biliary cirrhosis (PBC) - POISENDA filingCompletion of NDA filing planned in 1H 201501/13/2015
IMGN
6.33Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla GATSBY trialCancer - metastatic HER2+ gastric cancer Phase 3Data due 201501/13/2015
IMGN
6.33IMGN853 Cancer - ovarian cancer and relapsed endometrial cancerPhase 2Phase 2 to be initiated 201501/13/2015
INFI
15.29Duvelisib (IPI-145)Indolent non-Hodgkin lymphomaPhase 2Phase 2 topline data due 2H 201501/13/2015
INSY
49.72Dronabinol Oral SolutionAIDS-related anorexia NDANDA to be refiled 1Q 201501/13/2015
INSY
49.72CannabidiolEpilepsyPhase 3Phase 3 to be initiated 2H 201501/13/2015
INSY
49.72SubsysAcute post-operative painPhase 3Dose ranging trial to be initiated 1H 2015, with Phase 3 to be initiated 2H 2015. Data due 2016.01/13/2015
INSY
49.72BuprenorphineAcute pain in patients undergoing a bunionectomy procedurePhase 3Phase 3 to be initiated 1H 2015. Data due 2016.01/13/2015
INSY
49.72Buprenorphine/ NaloxonePhase 3Phase 3 to be initiated 201501/13/2015
INSY
49.72OndansetronPhase 3Phase 3 to be initiated 201501/13/2015
PTLA
28.16Andexanet alfaFactor Xa inhibitor reversal agentPhase 3Phase 3 first part of study met primary endpoint Jan 2015. Data from second part due mid-2015. BLA to be filed by late 201501/13/2015
SAGE
38.25SAGE-547Postpartum DepressionPhase 2aPhase 2a initiated mid 201501/13/2015
SGMO
13.41SB-728-1401HIV/AIDSPhase 2Phase 2 data due by the end of 201501/13/2015
TSRO
40.80NiraparibCancer - breastPhase 3Phase 3 initiated 1Q 2014.Ongoing01/13/2015
TSRO
40.80Niraparib - NOVA (Niraparib Ovarian) Cancer - ovarianPhase 3Phase 3 enrolment to be completed 1Q 2015. Data due 2015.01/13/2015
VCEL
3.10ixmyelocel-TStem cells - Dilated Cardiomyopathy Phase 2bCommenced enrolment Phase 2b Apr 2013. Enrolment due to be completed 2014. Topline data due 1Q 201501/13/2015
XLRN
39.24SotaterceptMyelodysplastic syndromes (MDS)Phase 2Phase 3 to be initiated 201501/13/2015
XLRN
39.24Sotatercept b -thalassemiaPhase 2Phase 3 to be initiated 201501/13/2015
XLRN
39.24SotaterceptEnd stage renal disease (ESRD) Phase 2bPhase 2b to be initiated 201501/13/2015
XLRN
39.24DalanterceptRenal Cell CarcinomaPhase 2Phase 2 data due 201501/13/2015
XNPT
8.60XP23829Moderate-to-severe plaque psoriasisPhase 2Phase 2 topline data due 3Q 201501/13/2015
XNPT
8.60XP23829Relapsing forms of multiple sclerosis (MS)Phase 3 planned01/13/2015
ARGS
7.72AGS-004 HIVPhase 2bPhase 2b trial did not meet endpoint - early Jan 201501/10/2015
ORPN
8.12CabalettaOculopharyngeal Muscular DystrophyPhase 2/3Phase 2/3 HOPEMD trial - randomization of Israeli patients has begun; patients are being enrolled into the first six-month phase in Canada; US trial requires IND filing, estimate 1Q 201501/10/2015
RIGL
2.14Fostamatinib Immune Thrombocytopenic Purpura (ITP)Phase 3Phase 3 initiated July 2014. Data due 1Q 201601/10/2015
RIGL
2.14FostamatinibIgA nephropathyPhase 2Phase 2 data due early 201601/10/2015
RIGL
2.14R348Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)Phase 2Phase 2 data due 1Q 201601/10/2015
SAGE
38.25SAGE-547SRSEPhase 1/2Phase 1/2 updated data released Jan 2015. 12 of 17 evaluable patients met efficacy endpoint. Pivotal trial to be initiated by mid-201501/10/2015
TNXP
6.20TNX-201Episodic tension-type headachePhase 2Phase 2 to be initiated 2Q 201501/10/2015
ALNY
93.42Patisiran APOLLOFamilial Amyloidotic Polyneuropathy (FAP) in Patients with ATTRPhase 3Phase 3 trial initiated Nov 2013, continues to enrol patients as of Nov 2014. Expects to complete enrolment in 201501/09/2015
ALNY
93.42RevusiranATTR in patients with familial amyloidotic cardiomyopathy (FAC)Phase 3Phase 3 ongoing. Present data in late 2015 from ongoing Phase 2 OLE study in patients with TTR cardiac amyloidosis. 01/09/2015
ALNY
93.42PatisiranFamilial Amyloidotic Polyneuropathy (FAP) in Patients with ATTRPhase 2 - open labelPhase 2 enrolment completed Sept 2013. Initial data released October 2014. Further data to be released mid 201501/09/2015
CNAT
5.34Emricasan Acute-on-Chronic Liver Failure (ACLF) Phase 2Phase 2 topline data released Jan 201501/09/2015
CNAT
5.34EmricasanPortal Hypertension Phase 2Phase 2 data due 3Q 201501/09/2015
CNAT
5.34EmricasanNon-alcoholic steatohepatitis (NASH)Phase 2Phase 2 trial initiated Mar 2014. Topline data due 1Q 201501/09/2015
CNAT
5.34EmricasanLiver CirrhosisPhase 2Phase 2 topline data due 2H 201501/09/2015
CNAT
5.34EmricasanLiver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)Phase 2bPhase 2b initiated May 2014. Initial open-label biomarker data expected 1H 2015.01/09/2015
CYTR
2.77AldoxorubicinCancer - AIDS-related Kaposi’s sarcomaPhase 2Phase 2 initiated Jan 2014. Prelim data due 2Q 2015. Placed on partial clinical hold Nov 2014. Interim data released Jan 2015 showed 4 of 6 patients demonstrated either a partial or complete response01/09/2015
GALE
1.66NeuVax (E75) - PRESENTCancer - low-to-intermediate HER2+ breast cancerPhase 3Initiated Phase 3 Jan 2012 under SPA. Enrolment due to be completed 1Q 201501/09/2015
GWPH
75.40GWP42006EpilepsyPhase 2Phase 2 to be initiated 1Q 201501/09/2015
GWPH
75.40EpidiolexLennox-Gastaut syndrome (LGS)Phase 3Two Phase 3 trials to be initiated 1Q 2015 with data from at least one of the two trials due by the end of 201501/09/2015
GWPH
75.40EpidiolexDravet SyndromePhase 2/3Top line Phase 3 data expected by the end of 201501/09/2015
INFI
15.29Duvelisib (IPI-145)Rheumatoid arthritisPhase 2Phase 2 failed to meet endpoint - Jan 201501/09/2015
IPXL
38.24IPX066Parkinson's ApprovedApproved Jan 8 201501/09/2015
KMDA
3.91KamRABProphylaxis of rabies diseasePhase 3Phase 2/3 data due 1H 2015. BLA filing due 201501/09/2015
LGND
54.67Captisol-enabled Delafloxacin IVABSSSIPhase 3Frist Phase 3 trial run by partner Melinta Therapeutics met endpoint. Data from second trial due 2H 201501/09/2015
NBIX
31.70Elagolix EndometriosisPhase 3First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 trial due towards the end of 201501/09/2015
OTIC
32.93OTO-104 Ménière's diseasePhase 2bPhase 2b data due 2Q 201501/09/2015
OTIC
32.93AuriProEar Tube Placement SurgeryPhase 3NDA filing due 1Q 201501/09/2015
PLX
1.99PRX-102Fabry diseasePhase 1/2Phase 1/2 interim data released Jan 2015. Full data due 4Q 201501/09/2015
RGLS
18.54RG-101 HCVPhase 2Phase 2 to be initiated 2Q 201501/09/2015
SGYP
2.87PlecanatideChronic idiopathic constipation (CIC)Phase 3Enrolment from first Phase 3 trial completed Jan 2015. Topline data due 2Q 2015. Topline data from second trial due 3Q 201501/09/2015
VSAR
17.30VRS-317Growth hormone deficiency, or GHD - pediatricPhase 3Phase 3 initiated early Jan 2015. interim 6 month height velocity analysis by mid-2016 and top line data on the 12 month height velocity primary endpoint is expected in early 2017.01/09/2015
VSTM
7.58VS-6063Mesothelioma prior to surgeryPhase 2Phase 2 data due 2Q 201501/09/2015
VSTM
7.58VS-6063KRAS-mutated NSCLCPhase 2Phase 2 data due 2H 201501/09/2015
ALKS
69.81ALKS 3831SchizophreniaPhase 2Phase 2 data released Jan 2015.Met primary endpoint, equivalence to olanzapine. Pivotal trial planned for 201501/08/2015
BIND
6.99 BIND-014 Cancer - KRAS mutant Non-small cell lung cancer (NSCLC)Phase 2Preliminary data due 2H 201501/08/2015
BIND
6.99 BIND-014 Cancer - Squamous histology NSCLCPhase 2Phase 2 enrolment to commence 1Q 2015, with preliminary data due late 201501/08/2015
BIND
6.99 BIND-014 Cancer - NSCLC broad patient populationPhase 2Phase 2 final overall survival data due in 1H 201501/08/2015
BIND
6.99 BIND-014 Cancer - Cholangiocarinoma, cervical cancer, bladder cancer and head and neck cancersPhase 2First patient enrollment in 2Q 201501/08/2015
CTIC
2.19TosedostatCancer - older patients with AML or high-risk myelodysplastic syndrome (MDS).Phase 2Phase 2 data due 2015, with pivotal trial to possibly commence in 2016 pending data and discussions with FDA01/08/2015
CTIC
2.19Pacritinib -PERSIST-1MyelofibrosisPhase 3Topline data due late 1Q 2015, with NDA filing late 2015. A second planned Phase 3 trial was initiated in March 2014 with enrolment due to be completed in mid-201501/08/2015
DERM
17.37CimziaModerate-to-severe plaque psoriasis Phase 3Phase 3 initiated Jan 2015. Data due 201701/08/2015
GNCA
6.55GEN-003Herpes simplex virus type 2 (HSV-2) Phase 1/2Phase 2 enrolment completed early Jan 2015. Topline data due late 2Q 201501/08/2015
BIOD
1.46BIOD-531 Type 2 diabetesPhase 2aPhase 2a data due early Jan 201501/07/2015
CANF
3.00CF101Psoriasis Phase 2/3Phase 2/3 topline data due 1Q 201501/07/2015
CANF
3.00CF102Cancer - advanced liver cancer second linePhase 2Phase 2 first patient dosed late Dec 2014. Enrolment to be completed by end of 201501/07/2015
KBIO
0.44KB001-ACystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (Pa) lung colonizationPhase 2Phase 2 data released early January 2015 did not meet endpoint. Development discontinued01/07/2015
RARE
52.21KRN23Tumor-induced osteomalacia (TIO)Phase 2Phase 2 to be initiated 1H 201501/07/2015
TNXP
6.20TNX-102 SL Fibromyalgia Phase 2b/3Endpoint not met - Sept 2014. Phase 3 to be initiated 2Q 201501/07/2015
TRVN
5.70TRV130 Moderate to severe acute painPhase 2bPhase 2 initiated May 2014. Topline data released Nov 2014. Second trial initiated Jan 2015. Topline data due mid 201501/07/2015
AKBA
10.61AKB-6548Anemia related to chronic kidney disease (CKD) who are undergoing dialysisPhase 2aPhase 2a enrolment completed Jan 2015. Data due 3Q 201501/06/2015
BCLI
3.80NurOwn Amytrophic lateral sclerosis (ALS)Phase 2aPhase 2a data released Jan 5 2015. 11 of 12 patients experienced an improvement in the rate disease progression01/06/2015
CEMP
25.49CEM-101 (solithromycin )CAPBPhase 3Phase 3 data released early Jan 2015 met the primary objective of statistical non-inferiority 01/06/2015
CYTR
2.77AldoxorubicinCancer - relapsed glioblastomaPhase 2Phase 2 initiated Nov 2013. Prelim data released Jan 2015 showed on CR from 1 of 12 patients, with tumor shrinkage and stable disease in some others. More data due at ASCO 201501/06/2015
GEVA
118.89SBC-103 Mucopolysaccharidosis IIIBPhase 1/2Phase 1/2 trial to be initiated early 2015. Preliminary data due 201501/06/2015
MSTX
0.47ANX-188Sickle cell diseasePhase 3Phase 3 initiated Jan 2013. Expect to complete enrolment 4Q 2015. Top-line data due 1Q 201601/06/2015
RLYP
36.81Patiromer for Oral Suspension (Patiromer FOS)HyperkalemiaPDUFAPDUFA October 21 201501/06/2015
RVNC
16.78RT002Moderate to severe glabellar (frown) linesPhase 2Phase 2 initiated January 2015. Data due late 201501/06/2015
AQXP
10.06AQX-1125 KINSHIPAtopic dermatitis (AD)Phase 2Phase 2 initiated late Dec 201401/01/2015
CANF
3.00CF101Rheumatoid arthritisPhase 3Phase 3 planned. Design of study completed late Dec 201401/01/2015
RPRX
8.61Androxal Secondary hypogonadismNDANDA to be filed 1Q 201501/01/2015
RPRX
8.61ProellexUterine fibroids (vaginal treatment)Phase 2bPhase 2b initiated Dec 201401/01/2015
RPRX
8.61ProellexUterine fibroids (oral treatment)Phase 2bPhase 2b initiated Dec 201401/01/2015
SYN
1.53 SYN-004C. difficile InfectionPhase 2Phase 2 to be initiated 1Q 201501/01/2015
TKMR
25.17TKM-PLK1Gastrointestinal Neuroendocrine Tumors (GI-NET) Phase 1/2Final data due mid-201501/01/2015
XENT
21.38Steroid eluting implantIn-office treatment of patients with recurrent disease due to polypsPhase 3Phase initiated late Dec 2014. Enrolment to be completed late 201601/01/2015
ATHX
2.04MultistemIschemic strokePhase 2Initiated 3Q 2011. Enrolment completed late Dec 2014. Initial data due around the end of 1Q 201512/30/2014
PTN
0.70Bremelanotidefemale sexual dysfunction (FSD)Phase 3Phase 3 initiated Dec 2014. Initial data due mid-201612/30/2014
LGND
54.67Captisol-Enabled MelphalanCancer - multiple myelomaNDA filingAnnounced Dec 26, 2014 that a NDA fiing has been made by partner SPPI 12/27/2014
SPPI
6.77Captisol-enabled, propylene glycol-free (PG-free) melphalanConditioning treatment prior to autologous stem cell transplant for patients with multiple myelomaNDA filingAnnounced Dec 26, 2014 that a NDA fiing has been submitted12/27/2014
ADMS
17.01NamzaricModerate to severe dementia of the Alzheimer's type.ApprovedApproved Dec 24 201412/26/2014
TLOG
5.83BirinapantCancer - 3rd line ovarianPhase 1/2Phase 1/2 trial to be completed at lower doses - announced Dec 16 201412/26/2014
BDSI
12.71BEMA BuprenorphineOpioid experienced patient groupNDAAnnounced Dec 23 2014 that they have submitted their NDA filing 12/24/2014
CMRX
38.26SUPPRESS trial of CMX001 Cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT)Phase 3Phase 3 dosing commenced Sept 2013. Data 2H 201512/24/2014
ENDP
78.87Buprenorphine Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequateApprovedAnnounced Dec 23 that they have submitted their NDA filing12/24/2014
PTCT
55.53Ataluren Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)Phase 3Top-line data due 4Q 2015. Rolling NDA filing commenced late Dec 201412/24/2014
ACHN
15.99RevusiranTreatment-naïve genotype 1 chronic hepatitis C virus (HCV) infectionPhase 2100 percent SVR4 results reported late December 2014 following six weeks of treatment12/23/2014
ACHN
15.99ACH-3422HCV Hepatitis C Phase 1/2Phase 1 data released late Dec 2014. 3.4 log reduction after 7 days, 4.8 log reduction after 14 days12/23/2014
BCRX
10.99Peramivir - Study 303INFLUENZA ACUTE ApprovedApproved Dec 22 201412/23/2014
PCYC
158.55IMBRUVICAWaldenström’s MacroglobulinemiaPDUFAPDUFA April 17, 201512/23/2014
RCPT
110.10RPC1063 - SUNBEAMRelapsing Multiple Sclerosis (RMS).Phase 3Phase 3 trial initiated Dec 2014. Expects to complete Phase 3 program in 201712/23/2014
RDUS
38.65Abaloparatide-SCOsteoporosisPhase 3Phase 3 top-line released late December 2014 - met endpoint. NDA filing due 2H 201512/23/2014
CBST
101.94Ceftolozane/ tazobactam ZERBAXAComplicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI)ApprovedApproved Dec 21 2014- priority review12/22/2014
ENTA
44.92ABT-450HCV - genotype 1ApprovedApproved December 19 201412/22/2014
OGXI
2.09OGX-427 in combination with gemcitabine and cisplatin Borealis-1Cancer - bladderPhase 2Released Phase 2 data mid Dec 201412/22/2014
CERS
5.29INTERCEPT PlateletsApprovedPMA approved Dec 18 201412/19/2014
IMGN
6.33Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trialCancer - 1st-line HER2+ Metastatic Breast Cancer Phase 3Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy12/19/2014
SGYP
2.87PlecanatideConstipation-predominant irritable bowel syndrome (IBS-C).Phase 2bFirst Phase 3 trial initiated mid-Dec 2014. Second Phase 3 trial to be initiated 1H 201512/19/2014
TLOG
5.83SHAPECancer - Cutaneous T-Cell LymphomaPhase 2Phase 2 trial initiated mid-Dec 201412/19/2014
BIOD
1.46BIOD-531 Type 2 diabetesPhase 1Announced Dec 2014 that they intend to release Phase 1 data and initiate a Phase 2b trial in 1H 2015 12/18/2014
CARA
10.83CR845 Uremic PruritusPhase 2Phase 2 topline data due 1H 201512/18/2014
CERS
5.29INTERCEPT B123PlasmaApprovedPMA approved Dec 16 201412/18/2014
CERU
8.25CRLX301Cancer - solid tumoursPhase 2Phase 2 patient dosing initiated mid Dec 201412/18/2014
CTIX
3.61CellceutixPlacque psoriasisPhase 2Given green light in November 2014 to initiate a Phase 2 trial12/18/2014
CTIX
3.61BrilacidinOral mucositisPhase 2Phase 2 trial to be initiated Dec 201412/18/2014
CTIX
3.61BrilacidinAcute Bacterial Skin and Skin Structure Infections (ABSSSI)Phase 2Will meet with the FDA in December 2014 regarding their planned Phase 3 trial12/18/2014
CTIX
3.61KevetrinCancer - variousPhase 2/3Phase 2/3 planned12/18/2014
CYCC
0.61Sapacitabine (SEAMLESS)Cancer - Acute myeloid leukemiaPhase 3Noted mid-Dec 2014 that interim analysis suggests that trial will fail12/18/2014
GTHP
0.20LuVivaDevice to detect cervical diseasePMANoted mid-Nov 2014 that "we also are anxiously awaiting word from the FDA on our PMA Amendment, which, based on FDA guidelines, could be received by January 24, 2015 or sooner."12/18/2014
ISIS
71.28ISIS-DMPK RxMyotonic Dystrophy Type 1 (DM1)Phase 1/2Announced Dec 16 that a Phase 1/2 trial has been initiated12/18/2014
OGXI
2.09OGX-427 in Combination with ABRAXANE plus Gemcitabine - Rainier TrialMetastatic Pancreatic CancerPhase 2Announced Dec 16 2014 that enrolment has been completed in their Phase 2 trial12/18/2014
POZN
7.05PA32540 and PA8140Cardiovascular patients at risk for developing aspirin-associated gastric ulcersCRLCRL Apr 25 2014. Further CRL issued Dec 17 2014 - due to deficiencies with facility. Intends to schedule a Type A meeting with FDA to address issues12/18/2014
RXII
1.17(RXI-109-1301)Anti-scarringPhase 2Phase 2 initiated November 2013. First data released Sept 2014. Announced completion of enrolment Dec 17 201412/18/2014
TTPH
33.61Eravacycline (TP-434)cIAI (complicated intra-abdominal infections)Phase 3Announced Dec 17, 2014 that their Phase 3 trial met endpoints, with NDA filing due by end of 201512/18/2014
TTPH
33.61Eravacycline (TP-434)cUTI - complicated urinary tract infectionsPhase 3Top-line data due mid 201512/18/2014
ACOR
43.76DalfampridinePost stroke deficitsPhase 2b/3Annonuced Dec 15, 2015 that a Phase 3 trial has been initiated12/16/2014
BLRX
1.83BL-8040Cancer - Acute myeloid leukemia (AML) Phase 2aPhase 2a enrolment began Jun 2013. Partial data released Dec 2013. Full data 2H 201512/16/2014
BLRX
1.83BL-8040Cancer - consolidation treatment for AML patientsPhase 2bPhase 2b to be initiated 1Q 201512/16/2014
BLRX
1.83BL-8040Cancer - AML patients with the FLT3-ITD mutationPhase 1/2Phase 1/2 to be initiated 1Q 201512/16/2014
EXEL
1.63VemurafenibCancer - malignant melanomaNDA filingAnnounced Dec 15 2015 that Genentech have submitted a NDA filing12/16/2014
LPCN
5.23LPCN 1021Men with low testosterone (Low T)Phase 3NDA filing due 2H 201512/16/2014
RARE
52.21rhGUS Mucopolysaccharidosis 7 (MPS 7) Phase 3Announced Dec 15 that a Phase 3 trial has been initiated. Data due 1H 2016.12/16/2014
SPHS
0.46PRX302Benign prostatic hyperplasia Phase 3Dec 15 2015, Independent Data Monitoring Committee (IDMC) reported that a predefined efficacy threshold following treatment was not achieved12/16/2014
VBLT
13.55VB-201Psoriasis Phase 2Phase 2 topline data due 1Q 201512/16/2014
VBLT
13.55VB-201Ulcerative colitisPhase 2Phase 2 topline data due 1Q 201512/16/2014
ZFGN
38.97BeloranibSevere obesity Phase 2bAnnounced Dec 15 that they have initiated their Phase 2b trial12/16/2014
CCXI
8.49CCX140Diabetic nephropathy Phase 2Phase 2 topline data released Dec 12 201412/15/2014
BLUE
95.92LentiGlobin - HGB-206Sickle diseasePhase 1/2Most likely to have initial data 1H 2015, as per JPM estimate12/12/2014
FOLD
8.31Migalastat HCl monotherapy (012)Fabry DiseasePhase 3Phase 3 data released August 2014. Endpoints met. Announced on December 11 that they intend to meet with the FDA during 1Q 2015 to discuss their possible NDA filing12/12/2014
KPTI
27.66SelinexorCancer - Diffuse Large B-Cell Lymphoma (DLBCL)Phase 2bPhase 2b initiated Dec 2014. Expects trial to be completed in two years (i.e. around end of 2016)12/12/2014
NKTR
14.62Etirinotecan pegol NKTR-102 (BEACON)Cancer - Metastatic Breast CancerPhase 3Maintained gudiance on Dec 11, 2014 that they expect Phase 3 topline data due 1Q 201512/12/2014
VICL
17.30Vaxfectin-formulated therapeutic vaccineHerpesPhase 1/2Announced Dec 11, 2014 that enrolment has been completed in their Phase 1/2 trial with data due mid 201512/12/2014
ACOR
43.76CVT-301OFF episodes of Parkinson’s disease (PD)Phase 3Announced December 10 that enrolment in their Phase 3 trial has been initiated for the treatment of OFF episodes in Parkinson’s disease (PD)12/11/2014
BMRN
97.69PEG-PALPhenylketonuria (PKU) Phase 3Announced Dec 10, 2014 that Phase 3 data are now due 1Q 2016.12/11/2014
NBIX
31.70NBI-77860Classic congenital adrenal hyperplasia (CAH) Phase 1/2Announced Dec 10 2014 that a Phase 1/2 trial in patients with CAH had been initiated12/11/2014
BDSI
12.71Clonidine gelPainful diabetic neuropathy (PDN) Phase 3Announced that they have completed the randomization of all patients, with Phase 3 topline data due by the end of March 201512/10/2014
BLUE
95.92 LentiGlobin β-ThalassemiaPhase 1/2Data presented at ASH 2014 showed that first four patients are transfusion free12/10/2014
DVAX
17.54AZD1419AsthmaPhase 2aAnnounced in December 2014 that a Phase 2a trial in 1H 201512/10/2014
INCY
79.90BaricitinibRheumatoid arthritisPhase 3Data from first Phase 3 trial met primary endpoint December 2014. Data from other trials due 201512/10/2014
IRWD
15.98IW-9179GastroparesisPhase 2aPhase 2a initiated December 2014. Data due 1H 201612/10/2014
MEIP
3.69Pracinostat in combination with VidazaElderly patients with newly diagnosed acute myeloid leukemia (AML)Phase 2Preliminary data from this open-label trial was released at ASH December 2014. Phase 3 is planned12/10/2014
MEIP
3.69Pracinostat in combination with Vidaza First line intermediate-2 or high-risk Myelodysplastic SyndromePhase 2Phase 2 topline data expected March 201512/10/2014
ZGNX
1.28 Abuse deterrent formulations of Zohydro ERModerate to severe painPDUFAPDUFA January 30 201512/08/2014
QLTI
4.41QLT091001Impaired Dark Adaptation (IDA)Phase 2aPhase 2a data released December 201412/07/2014
THLD
3.52TH-302Cancer - multiple myeloma Phase 1/2Initiated dosing in final part of trial July 2014. Initial data presented at ASH 201412/07/2014
ADMA
11.03RI-002Primary Immune Deficiency DiseasesPhase 3Phase 3 prelim data released December 2014 met endpoint. Final data due 1Q 2015. BLA filing planned for 1H 201512/05/2014
APRI
2.08RayVa Secondary Raynaud's PhenomenonPhase 2aPhase 2a initiated December 2014. Expects to complete trial 2015. 12/05/2014
CLDX
22.75Glembatumumab vedotinCancer - melanomaPhase 2Phase 2 initiated December 201412/05/2014
EARS
3.70AM-101Acute inner ear tinnitusPhase 3Phase 3 topline data due early 201612/05/2014
EARS
3.70AM-111Acute inner ear hearing lossPhase 3Pivotal trial to be initiated mid 201512/05/2014
INCY
79.90Jakafi (ruxolitinib) (RESPONSE)Polycythemia VeraApprovedApproved December 4 201412/05/2014
NERV
5.15MIN-101SchizophreniaPhase 2bPhase 2b trial to be initiated in 1H 201512/05/2014
XON
27.34Ad-IL-12CancerPhase 2Updated data released at AACR Tumor Immunology and Immunotherapy Meeting December 201412/05/2014
GWPH
75.40SativexCancer painPhase 3Phase 3 initial topline data expected early 201512/03/2014
GWPH
75.40GWP42004Type 2 diabetesPhase 2bEstimated completion date 201612/03/2014
GWPH
75.40GWP42003SchizophreniaPhase 2Estimated completion date 2H 201512/03/2014
GWPH
75.40SativexMultiple Sclerosis (MS) spasticityPhase 3Phase 3 Special Protocol Assessment (SPA) ongoing with FDA for proposed Sativex Phase 3 trial 12/03/2014
LPTN
2.96iSONEPWet-AMDPhase 2Reported Dec 2 2014 that Phase 2 enrolment has been completed. Data due 2Q 201512/03/2014
PBYI
212.69PB272Extended adjuvant HER2-positive early stage breast cancerPhase 3NDA filing delayed due to 1Q 2016 following FDA request for data from preclinical carcinogenicity studies 12/03/2014
PRTA
21.51NEOD001AL AmyloidosisPhase 3Phase 1/2 postive data released December 2 2014. Phase 3 initiated.12/03/2014
CANF
3.00CF101GlaucomaPhase 2Phase 2 data due 2Q or 3Q 201512/02/2014
EXEL
1.63CabozantinibCancer - Castration-Resistant Prostate CancerPhase 3Phase 3 COMET-2 trial did not meet endpoint December 1 201412/02/2014
EXEL
1.63Cabozantinib - (METEOR)Cancer - metastatic renal cell cancer (RCC)Phase 3Phase 3 initiated May 2013. Enrollement due to be completed 2014. Data due 2Q 201512/02/2014
FLXN
21.78FX006Osteoarthritis of the knee Phase 2bPhase 2b initiated April 2014. Placed on clinical hold Sep 2015. Hold lifted December 201412/02/2014
GLMD
6.41AramcholNon-Alcoholic Steatohepatitis (NASH)Phase 2bInitiate Phase 2b 4Q 2014. Interim analysis due 2H 2015. Final data due 2H 201612/02/2014
NKTR
14.62 BAX 855 Hemophilia ABLACompany announced Dec 2 2014 that BAX has submitted their BLA12/02/2014
QURE
20.53AAV5 Gene therapyhemophilia BPhase 1/2Phase 1/2 to be initiated early 2015 with interim data due mid 201512/02/2014
AVNR
16.96AVP-825Acute migraineCRLCRL November 26 2014 - likely to resubmit 1H 201511/27/2014
ISIS
71.28ISIS-SMNRxChildren with spinal muscular atrophy (SMA)Phase 3Phase 3 initiated July 2014. Additional Phase 3 study initiated Nov 201411/27/2014
PRTO
10.58PRT-201 Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF)Phase 3Phase 3 initiated July 2014. Data due 1Q 201711/27/2014
XOMA
3.48XOMA 052 Gevokizumab EYEGUARD-ANon-Infectious Uveitis (Active)Phase 3Data due 201511/27/2014
XOMA
3.48XOMA 052 Gevokizumab EYEGUARD-BBehcet's uveitisPhase 3Data expected 1Q 201511/27/2014
XOMA
3.48XOMA 052 Gevokizumab EYEGUARD-C Non-Infectious Uveitis ( Controlled )Phase 3Data due 201511/27/2014
EXEL
1.63XL184 cabozantinib (CELESTIAL)Cancer - advanced hepatocellular cancer (HCC)Phase 3Phase 3 initiated Sept 2013. Data due 201711/25/2014
NKTR
14.62FovistaWet-AMDPhase 3Phase 3 initial topline data due 201611/25/2014
OPHT
55.52FovistaWet-AMDPhase 3Phase 3 initial topline data due 201611/25/2014
OPXA
0.83Tovaxin (Tcelna)Secondary Progressive MS (SPMS)Phase 2bPhase 2b initiated Sept 2012. 100 patients enrolled as of Nov 2013. Top-line data 2H 201611/25/2014
ALDX
8.94NS2 Sjögren-Larsson Syndrome (SLS)Phase 3Phase 3 planned for 2014. Data due 2H 201511/24/2014
ALDX
28.05NS2Acute anterior uveitisPhase 2Phase 2 planned for 2014. Data due 2H 201511/24/2014
DSCI
8.64DSC127 Diabetic foot ulcersPhase 3Phase 3 to be completed 2H 201611/24/2014
SGMO
13.41CERE-110 Alzheimer's DiseasePhase 2Phase 2 data due 201511/24/2014
SNTA
2.47STA-9090 Ganetespib - GALAXY-2Cancer - NSCLCPhase 3Phase 3 trial initiated Apr 2013 with first analysis due 2H 2015, second analysis due 1H 201611/24/2014
ACRX
6.47ARX-04Moderate-to-severe acute painPhase 3Phase 3 to be initiated 1Q 2015. Data 2H 201511/23/2014
ALDR
28.05Clazakizumab Psoriatic arthritis (PsA)Phase 2Phase 2 data released 4Q 201411/23/2014
AMPE
4.73OptinaDiabetic Macula EdemaPhase 2bPhase 2b trial completed enrolment Feb 2014.Data due 4Q 2014 or early 201511/23/2014
AMPE
4.73AmpionOsteoarthritis of the KneePhase 3Phase 3 data released Aug 2013. Final pivotal trial ongoing. Data due 1Q 201511/23/2014
ARDX
26.62TenapanorHyperphosphatemia in end stage renal disease (ESRD) patients on hemodialysisPhase 2bPhase 2b data due 1Q 201511/23/2014
ARDX
26.62TenapanorLate-stage chronic kidney disease (CKD) Phase 2aPhase 2a data due 2H 201511/23/2014
BIND
6.99 BIND-014 Cancer - Prostate CancerPhase 2Ongoing11/23/2014
EGRX
18.92RTU bivalirudin liquidNDA filingNDA filing due 2Q 201511/23/2014
ESPR
46.31ETC-1002-009HypercholesterolemiaPhase 2b Data due March 201511/23/2014
ESPR
46.31ETC-1002-014Hypercholesterolemia and hypertensionPhase 2Phase 2 data due 2Q 201511/23/2014
GWPH
75.40GWP42003Ulcerative colitis.Phase 2aPrelim data released 4Q 201411/23/2014
NBS
3.58AMR-001Left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI)Phase 2Phase 2 data released Nov 201411/23/2014
NLNK
39.40HyperAcute Pancreas - IMPRESSSurgically resected pancreatic cancerPhase 3Enrloment completed Sept 2013. First of two interim analyses completed March 2014. Trial to continue as planned. Second analysis due 1Q 201511/23/2014
NPSP
45.64NPSP795 Autosomal dominant hypocalcemia or ADHPhase 2Phase 2 initiated August 2014. Preliminary top-line data due early 201511/23/2014
OMER
22.86OMS721 Thrombotic microangiopathies (TMAs)Phase 2Phase 2 preliminary data due end of 201411/23/2014
PCYC
158.55IMBRUVICA RESONATE™-17Deletion 17pPhase 2Phase 2 data due late 201411/23/2014
PCYC
158.55IMBRUVICA RESONATE -2Cancer - newly diagnosed elderly CLL/SLL patientsPhase 3Phase 3 data due 2H 201511/23/2014
PCYC
158.55IMBRUVICA in combination with bendamustine and rituximab - HELIOS (CLL3001)Cancer - Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL)Phase 3Phase 3 data due 1H 201511/23/2014
SCMP
15.18Rescula (unoprostone isopropyl) Retinitis pigmentosaPhase 3Phase 3 interim data due 1Q 201511/23/2014
STEM
1.05HuCNS-SC cellsAge-Related Macular DegenerationPhase 1/2Phase I/II dosing initiated Jun 2012. First patient enrolled Oct 2012. Enrolment completed June 2014. Phase 2 to be initiated late 2014 or early 201511/23/2014
ZIOP
7.24Palifosfamide MATISSE studyCancer - small cell lung SCLCPhase 3Initiated Phase 3 Jun 2012. Ongoing. Interim data due 1H 201511/23/2014
AEZS
0.52AEZS-108Cancer - Endometrial Phase 3Phase 3 trial initiated Jul 2013 under SPA, Interim analysis due 1H 201511/22/2014
CLVS
64.74Rucaparib ARIEL2Cancer - ovarian second linePhase 2Phase 2 dosing initiated Oct 2013. Interim data released November 2014. Enrolment due to be completed early 201511/22/2014
PTCT
55.53Spinal Muscular Atrophy (SMAPhase 1/2Phase 1/2 initiated November 201411/22/2014
SGYP
2.87SP-333Opioid-induced constipation (OIC)Phase 2Phase 2 initiated Oct 2013. Enrollment completed July 2014. Data released Nov 201411/22/2014
TTNP
0.49ProbuphineOpioid dependencePhase 3PDUFA date Apr 30 2013 under priority review. Adcom Mar 21 2013 resulted in favourable vote 10-4. New Phase 3 trial initiated July 2014, due to be completed mid 2015, NDA due late 2015.11/22/2014
ADHD
6.40MDX (Metadoxine Extended Release (MG01CI))Fragile X SyndromePhase 2bPhase 2b enrolment due to be completed 1Q 201511/19/2014
ADHD
6.47MDX (Metadoxine Extended Release (MG01CI))Pediatric ADHDPhase 2bPhase 2b enrolment due to be completed by end of 201411/19/2014
AFMD
5.18AFM13Hodgkin LymphomaPhase 2Phase 2 to be initiated early 201511/19/2014
CLDX
22.75CDX-110 (rindopepimut) in combination with Avastin - ReACTCancer- glioblastoma multiforme (GBM) refractoryPhase 2Phase 2 inteirm data released Nov 201411/19/2014
GALE
1.66GALE-401Essential Thrombocythemia (ET)Phase 2Phase 2 initiated September 2014. Top-line data due mid 2015.11/19/2014
THLD
3.52TH-302Cancer - glioblastoma (GBM)Phase 1/2Phase 1/2 interim data released Nov 201411/19/2014
AGRX
7.54TwirlaContraceptive patch Phase 3Phase 3 data due 1Q 2016. CRL issued 201311/15/2014
ANTH
2.08BlisibimodLupusPhase 3Missed primary endpoints in Phase 2b trial Jun 2012. Phase 3 trial initiated Mar 2013. Expects enrolment to be completed during 1H 201511/15/2014
ANTH
2.08BlisibimodIgA nephropathyPhase 2Phase 2 initiated Jun 2013. Interim data pending partnership negotiations11/15/2014
ARGS
7.72AGS-003 ADAPT Trial Phase 3AGS-003 Phase 3 ADAPT Trial on track to complete enrollment 1Q 201511/15/2014
CERU
8.25CRLX101 in Combination with Chemotherapy and Radiation Rectal CancerPhase 1b/2Data due 1Q 201511/15/2014
CERU
8.25CRLX101, in combination with AvastinCancer - relapsed ovarianPhase 2Data due 1Q 201511/15/2014
CERU
8.25CRLX101, in combination with AvastinCancer - Relapsed Renal Cell CarcinomaPhase 2Data due by end of 201511/15/2014
EVOK
6.30EVK-001Female diabetic gastroparesisPhase 3Phase 3 initiated April 2014. Data due mid 201511/15/2014
GLMD
6.41AramcholCholesterol GallstonesPhase 2aPhase 2a initiated Nov 2014, data due 1H 201511/15/2014
HTBX
4.09HS-110Cancer - NSCLC non-small cell lung cancer Phase 2Phase 2 trial initiated Sept 2014. Interim data due 1H 201511/15/2014
INNL
7.50XaraColl Post-operative painPhase 3Phase 3 to be initiated 1H 201511/15/2014
MRNS
10.99GanaxoloneEpilepsyPhase 3Phase 3 top-line data due 1H 201511/15/2014
MRNS
10.99GanaxoloneFragile X SyndromePhase 2Phase 2 top-line data due mid-201511/15/2014
OCRX
6.22OCR-002 (IV)Hepatic encephalopathyPhase 2bPhase 2b enrolment to be completed mid-201511/15/2014
OCRX
6.22OCR-002 Cirrhosis and upper gastrointestinal bleedingPhase 2aPhase 2a enrolment completed as of 4Q 201411/15/2014
ONTX
3.53Oral rigosertibCancer - MDS low riskPhase 3Phase 3 to be initiated 2H 2015 - pending results and funding11/15/2014
PBYI
212.69PB272 HER2-positive breast cancer first linePhase 2Phase 2 failed to meet endpoint, Nov 2014.11/15/2014
PFNX
6.74PF582Biosimilar candidate to Lucentis for retinal diseasesPhase 1/2Phase 1/2 interim data due 1Q 2015. Phase 3 to be initiated mid 201511/15/2014
SCYX
11.67SCY-078Candida infectionsPhase 2Phase 2 to be initiated by the end of 201411/15/2014
SYN
1.53SYN-004Constipation-Predominant Irritable Bowel Syndrome (C-IBS)Phase 2Phase 2 to commence 1H 2015. 11/15/2014
VBLT
13.55VB-111Cancer - recurrent glioblastoma, or rGBMPhase 2Phase 3 to be initiated 1H 201511/15/2014
AAVL
39.92AVA-101Wet-AMDPhase 2aPhase 2a ongoing11/13/2014
CLDN
17.03MYDICAR - CUPID 2 TrialIschemic or dilated cardiomyopathyPhase 2bPhase 2b data due April 201511/13/2014
CLDN
17.03MYDICAREnd-stage renal disease (ESRD)Phase 2aPhase 2a trial possibly going to be initiated 201511/13/2014
CNCE
#N/ACTP-499 Diabetic Kidney DiseasePhase 2Phase 3 planned. Needs partner11/13/2014
DERM
17.37DRM04Primary axillary hyperhidrosisPhase 2bPhase 2b data due 1H 201511/13/2014
DERM
17.37DRM01AcnePhase 2aPhase 2b to be initiated 1H 201511/13/2014
DPRX
11.50LocilexMild infections of diabetic foot ulcersPhase 3Second Phase 3 under SPA initiated July 2014. Data due 1Q 2015. NDA filing due 2H 201511/13/2014
EGLT
8.54Egalet-001Abuse-Deterrent MorphineBioequivalence StudiesPhase 3 to commence 1Q 2015. NDA planned for mid-2016.11/13/2014
EGLT
8.54Egalet-002Moderate to severe chronic painPhase 3Phase 3 trial planned for 1Q 201511/13/2014
LJPC
20.25GCS-100Chronic kidney diseasePhase 2Phase 2b to commence 1Q 201511/13/2014
LJPC
20.25LJPC-501Catecholamine-resistant hypotension (CRH).Phase 3Phase 3 to commence 1Q 201511/13/2014
MEIP
3.69Pracinostat and Vidaza or DacogenMyelodysplastic SyndromePhase 2Ongoing11/13/2014
OCUL
26.35OTX-DP Ocular inflammation and pain following cataract surgeryPhase 3Phase 3 data due 1Q 201511/13/2014
OCUL
26.35OTX-DPGlaucoma and ocular hypertensionPhase 2bPhase 2b initiated November 201411/13/2014
OCUL
26.35OTX-DPAllergic conjunctivitisPhase 2Phase 2 data released November 201411/13/2014
RVNC
16.78RT001 Lateral canthal lines (crow’s feet lines)Phase 3Phase 3 planned for early 201511/13/2014
VTAE
14.94VTP-34072Type 2 DiabetesPhase 2Phase 2 initiated July 2014. Data due 1H 201511/13/2014
ACAD
31.88PimavanserinParkinson’s disease psychosis (PDP)Phase 2NDA filing due 1Q 201511/12/2014
ACRX
6.47ZalvisoPost-operative pain following open abdominal surgery and hip or knee replacement surgeryCRLCRL Jul 26 2014. NDA resubmission due 1Q 201511/12/2014
AERI
29.92RoclatanGlaucomaPhase 3Phase 3 to be initiated mid 201511/12/2014
ARQL
1.10Tivantinib (ARQ 197) METIV-HCC trialInoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior TherapyPhase 3Phase 3 SPA agreed upon. Enrolment initiated Jan 2013. Dosage reduced following recommendation from DMC. DMC recommended continuation of trial Jan 2014. Patient accrual end of 201511/12/2014
ATHX
2.04MultistemAcute myocardial infarctionPhase 1Phase 2 planned for 201511/12/2014
CARA
10.83IV CR845Acute painPhase 3Phase 3 planned for early 201511/12/2014
CYCC
0.61SapacitabineCancer - Myelodysplastic syndromesPhase 2Phase 2b to be initiated 201511/12/2014
GALE
1.66NeuVaxCancer - HER2 3+ Breast CancerPhase 2Phase 2 initiated Nov 2014. Enrollment due to be completed 2H 201611/12/2014
MACK
9.59MM-111Cancer - gastric, esophageal and gastroesophageal cancers Phase 2Phase 2 initiated July 2013. Data due 201511/12/2014
MACK
9.59MM-398 NAPOLI-1Cancer - second line pancreaticPhase 3NDA filng due 2014 or early 201511/12/2014
MACK
9.59MM-141Cancer - front line pancreatic cancerPhase 2Phase 2 to be initiated 201511/12/2014
MGNX
32.44Margetuximab (MGAH22)Cancer - Advanced gastroesophageal Phase 3Phase 3 to commence 3Q 201511/12/2014
MGNX
32.44MGA271CancerPhase 2Phase 2 to be initiated 201511/12/2014
PBYI
212.69PB272 Neoadjuvant treatment for patients with HER2-positive breast cancer (NSABP FB-7)Phase 2Phase 2 data due 4Q 201411/12/2014
PBYI
212.69PB272 in combination with toriselFourth line HER2-positive metastatic breast cancerPhase 2Phase 2 additional data due 2H 2014. Phase 3 initiation due 201511/12/2014
PBYI
212.69PB272HER2-negative breast cancer patients who have a HER2 mutationPhase 2Data due 201511/12/2014
PBYI
212.69PB272 HER2+ MBC that has metastasized to the brainPhase 2Data due 201511/12/2014
PTLA
28.16Betrixaban (The APEX Study)Venous thromboembolism (VTE) PreventionPhase 3Complete patient enrollment in APEX by the end of 2015. Data due early 201611/12/2014
PTLA
28.16Cerdulatinib (PRT2070)Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia.Phase 1/2 Ongoing11/12/2014
SUPN
8.57SPN-812ADHDPhase 2bPhase 2b due to commence 2H 201511/12/2014
SUPN
8.57SPN-810Impulsive Aggression in ADHDPhase 2bPhase 3 due to commence 2H 201511/12/2014
TRVN
5.70TRV027 - BLAST-AHFAcute heart failurePhase 2bPhase 2b data due 4Q 201511/12/2014
XNCR
17.41XmAb5871Moderate to severe rheumatoid arthritisPhase 2aPhase 2 data due 2H 201411/12/2014
ZFGN
38.97BeloranibHypothalamic injury-associated obesity (HIAO)Phase 2aPhase 2a to be completed 201511/12/2014
ASPX
58.46SD-809Tardive Dyskinesia (TD)Phase 2/3Phase 2b topline data due mid 2015. Data from Phase 3 trial due 201611/11/2014
DCTH
1.23Melphalan Hepatic Delivery System (Melphalan HDS)Hepatocellular carcinoma (HCC)Phase 2Phase 2 data due 1H 201511/11/2014
GTXI
0.62GTx-758 CapesarisCancer - ProstatePhase 2Placed on clinical hold. Hold lifted May 2012. Phase 2 trial continued on LOWER doses. Ongoing. Prelim data released Jan 2014. Data due 2Q 201511/11/2014
INO
8.61VGX-3100Cervical dysplasiaPhase 2Phase 3 to be initiated early 201611/11/2014
KPTI
27.66SelinexorRichter's transformation (SIRRT)Phase 2Phase 2 initiated November 201411/11/2014
LPCN
5.23LPCN 1111Oral testosterone productPhase 2aPhase 2b to be initiated 1Q 201511/11/2014
RARE
52.21Triheptanoin Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)Phase 2Phase 2 initiated February 2014. Data due 201511/11/2014
RARE
52.21TriheptanoinGlucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)Phase 2Phase 2 initiated March 2014. Data due 201511/11/2014
RARE
52.21KRN23X-linked Hypophosphatemia (XLH)Phase 2Phase 2 initiated July 2014. Interim data due 2015.11/11/2014
TKAI
11.89GaleteroneCancer - castration-resistant prostate cancer (CRPC)Phase 2Phase 3 to be initiated 1H 201511/11/2014
AEZS
0.52Macimorelin AcetateAdult Growth Deficiency CRLCRL Nov 5 201411/08/2014
ANAC
34.15AN2728Mild-to-moderate atopic dermatitisPhase 3Phase 3 data due 2H 201511/08/2014
CLVS
64.74Rociletinib Cancer - 2nd line T790M+ NSCLC Phase 2/3NDA filing due mid 201511/08/2014
CUR
3.12NSI-189DepressionPhase 2Phase 2 to be initiated 2Q 201511/08/2014
DSCO
1.31AerosurfRespiratory Distress Syndrome - ModeratePhase 2aPhase 2a data due 1Q 201511/08/2014
GERN
3.23ImetelstatCancer - essential thrombocythemiaPhase 2Not pursuing future development11/08/2014
GERN
3.23ImetelstatMyelofibrosisPhase 2Phase 2 clinical hold lifted Nov 2014. Phase to be initiated 1H 201511/08/2014
GNCA
6.55GEN-004Universal vaccine candidate against pneumococcusPhase 2Phase 2 trial initiated September 2014. Interim data due mid 201511/08/2014
HPTX
24.95RavictiHepatic encephalopathyPhase 2Phase 3 to be initiated 2Q 201511/08/2014
HRTX
8.25APF530 - SustolPrevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)CRLCRL Mar 28 2013. Refile 201511/08/2014
ICPT
165.76Obeticholic acid (OCA)Primary Sclerosing Cholangitis (PSC)Phase 2Phase 2 to be initiated by end of 201411/08/2014
IMMU
4.73Clivatuzumab tetraxetanCancer - PancreaticPhase 3Phase 3 data due mid 201611/08/2014
IMMU
4.73Epratuzumab (EMBODY 2)LupusPhase 3Data due 1H 201511/08/2014
INSM
14.89ARIKAYCENon-tuberculous Mycobacterial Lung DiseasePhase 3Clinical hold lifted Jan 2012. Topline data released March 26 2014. Missed primary endpoint. Met key secondary endpoint. Two Phase 3 trials to be initiated, prelim data due mid-2016 and in 2017.11/08/2014
NKTR
14.62NKTR-181Chronic painPhase 2Missed endpoint Sept 2013 but Phase 3 planned for 4Q 201411/08/2014
PTCT
55.53Ataluren Nonsense mutation cystic fibrosisPhase 3Phase 3 initiated July 2014. Data due 2H 201611/08/2014
RMTI
10.81Soluble Ferric PyrophosphateIron deficiencyPDUFAPDUFA January 24 2015. Adcom meeting Nov 6 2014 voted 8-3 in favour11/08/2014
RPTP
9.29DR CysteamineNon-alcoholic fatty liver disease (NAFLD) in childrenPhase 2bPhase 2b initiated Jun 2012. Enrolment target hit Jan 2014. Data due 201511/08/2014
TLOG
5.83BirinapantMyelodysplastic syndromes, or MDSPhase 2Phase 2 data due mid 201511/08/2014
VSAR
17.30VRS-317Growth hormone deficiency, or GHD - adultPhase 2/3Phase 2/3 to be initiated in 2H 2015.11/08/2014
BLRX
1.83 BL-7010Celiac diseasePhase 1/2Efficacy trial to be initiated 2H 2015.11/06/2014
DCTH
1.23Melphalan Hepatic Delivery System (Melphalan HDS)Ocular Melanoma (OM) Liver MetastasesPhase 3Phase 3 to be initiated mid 201511/06/2014
INSV
0.19BromSite (ISV-303) Pain after cataract surgeryPhase 3Phase 3 data released Dec 2013. NDA filing due 1Q 201511/06/2014
MDCO
28.40CARBAVANCESerious Bacterial Infections Due to Gram-Negative BacteriaPhase 3Phase 3 initiated Nov 2014. Data due 201611/06/2014
TRGT
2.52TC-6499 Diabetic GastroparesisPhase 1/2Phase 1/2 initiated 4Q 2013. Topline data due 1H 201511/06/2014
AQXP
10.06AQX-1125 LEADERSHIPBladder pain syndrome/interstitial cystitis (BPS/IC). Phase 2Phase 2 data due 1H 201511/05/2014
AQXP
10.06AQX-1125 FLAGSHIPChronic obstructive pulmonary disease (COPD)Phase 2Phase 2 data due 1H 201511/05/2014
ARRY
7.11Binimetinib (NEMO)Cancer - NRAS melanomaPhase 3Phase 3 initiated Jul 2013. NDA filing expected 1H 201611/05/2014
CORT
2.89Corlux - KorlymCancer - triple-negative breast cancerPhase 1/2Phase 1/2 data due 201511/05/2014
EXEL
1.63CabozantinibCancer - EGFR Wild-Type Non-Small Cell Lung CancerPhase 2Phase 2 data released Nov 201411/05/2014
IRWD
15.98 IW-3718 Gastroesophageal reflux disease (GERD) Phase 2aPhase 2a initiated March 2014. Data due early 201511/05/2014
IRWD
15.98LinaclotideChronic idiopathic constipation (CIC)Phase3Phase 3 data due 201611/05/2014
IRWD
15.98LinaclotideOpioid-induced constipation (OIC)Phase 2Phase 2 initiated Oct 2014. Data due 2H 2015.11/05/2014
LXRX
0.92LX4211Type 1 DiabetesPhase 3Phase 3 planned for early 201511/05/2014
RCPT
110.10RPC1063 -RADIANCERelapsing Multiple Sclerosis (RMS). Phase 3Phase 2 Top-line data released June 2014. Phase 3 is ongoing.11/05/2014
RCPT
110.10RPC1063Ulcerative Colitis (UC) Phase 2Phase 2 top-line data met endpoints - Oct 2014. Phase 3 planned for 201511/05/2014
RCPT
110.10RPC4046 Eosiniphilic EsophagitisPhase 2Phase 2 topline data due 1H 201611/05/2014
RCPT
110.10RPC1063Chron's diseasePhase 2Phase 2 planned for 201511/05/2014
TTHI
6.83ELND005Bipolar I Disorder (BPD 1)Phase 2Phase 2 data released Nov 201411/05/2014
XOMA
3.48XOMA 052 gevokizumabPyoderma GangrenosumPhase 2Initiated Phase 3 trial November 201411/05/2014
ALDR
28.05ALD403 MigrainePhase 2b Phase 2b data due 2H 201511/04/2014
ARNA
4.55Lorcaserin Smoking cessationPhase 2Phase 2 initiated March 2014. Data released Nov 201411/04/2014
MCUR
9.59CureXcellDiabetic Foot UlcersPhase 3Phase 3 data due 2H 201511/04/2014
MCUR
9.59CureXcellVenous Leg Ulcers Phase 3Phase 3 initial data due 2H 2015. Final data 2H 201611/04/2014
NBIX
31.70Elagolix Uterine FibroidsPhase 2bPhase 2b initiated Mar 2013. Ongoing as of Feb 2014. Data due 2015.11/04/2014
NBIX
31.70VMAT2 NBI-98854 - Kinect 3Tardive dyskinesiaPhase 3Phase 3 initiated Oct 2014. Data due 2H 201511/04/2014
THLD
3.52TH-302 MAESTROCancer - PancreaticPhase 3Phase 3 SPA agreed upon with FDA. Initiated Jan 2013. Topline data due 201611/04/2014
THLD
3.52TH-302Cancer - soft tissue sarcoma (406 trial)Phase 3Initiated Ph3 Sept 2011, under SPA, interim data due September 2014. Topline data due 1Q 201611/04/2014
MSTX
0.47ANX-188Acute limb ischemia (ALI)Phase 2Initiated Phase 2 March 2014. Expect to complete enrolment 2H 201611/03/2014
MSTX
0.47MST-188 Heart Failure Phase 2Phase 2 to be initiated 2H 2014. Interim data due 2H 201511/03/2014
AUXL
35.95XIAFLEXAdhesive Capsulitis (“Frozen Shoulder syndrome”)Phase 2bPhase 2b data due 1Q 201510/31/2014
INCY
79.90Ruxolitinib - JANUS 1 and JANUS 2Cancer - PancreaticPhase 3Phase 3 data due 201610/31/2014
ALKS
69.81ALKS 5461Major depressive disorder Phase 2Phase 3 (two trials) initiated Jun 2014. Data due 2016. Third Phase 3 trial initiated mid 2014. Data due 2016.10/30/2014
CEMP
25.49Taksta CEM-102Prosthetic joint infection (PJI) Phase 2Plans to meet FDA in 4Q 2014 to discuss Phase 3 trial 10/30/2014
IMMU
4.73ISACTUZUMAB GOVITECAN (IMMU-132) Cancer - metastatic solid cancersPhase 2Phase 2 data released Oct 201410/30/2014
SNTA
2.47Ganetespib - I-SPY 2 TRIAL Cancer - breastPhase 2Phase 2 initiated Oct 201410/30/2014
AKBA
10.61AKB-6548Anemia associated with chronic kidney disease (CKD)Phase 2bPhase 3 planned for 2015. Phase 2b data released Oct 2014.10/29/2014
DRRX
0.91RemoxyChronic painCRLCRL Jun 23, 2011. Resubmission no earlier than mid-2015. PFE returned rights to PTIE in late Oct 2014.10/29/2014
HTBX
4.09HS-410Cancer - bladder cancerPhase 2Phase 2 initiated Oct 2014. Data due 3Q 201610/29/2014
PTIE
1.95RemoxyChronic painCRLCRL Jun 23, 2011. Resubmission no earlier than mid-2015. PFE returned rights to PTIE in late Oct 2014.10/29/2014
SRPT
12.18EteplirsenDuchenne muscular dystrophyNDANDA to be filed by mid 201510/29/2014
ATRA
23.14PINTA 745Protein-energy wastingPhase 2Phase 2 initial data due 2H 201510/25/2014
BMRN
97.69BMN-701Pompe DiseasePhase 2/3Phase 2/3 enrolment due to be completed 1H 2015. Data due 2H 201510/25/2014
BMRN
97.69BMN-673Cancer -gBRCA breast cancer Phase 3Phase 3 initiated Oct 2013: Enrollment completion due 2H 201510/25/2014
BMRN
97.69BMN-111AchondroplasiaPhase 1/2Phase 2 initiated Jan 2014: Data on first three cohorts in Phase 1/2 with BMN 111 for the treatment of achondroplasia due 2Q 201510/25/2014
BMRN
97.69BMN 190Batten DiseasePhase 1/2Phase 1/2 initiated Sep 2013. Data due 2H 201510/25/2014
CALA
19.70CB-839Cancer - variousPhase 1Phase 2 planned for late 2015 or early 201610/25/2014
CLVS
64.74LucitanibCancer - breastPhase 2Phase 2 dosing initiated Oct 201410/25/2014
DBVT
25.35Viaskin Peanut Peanut allergyPhase 2bPhase 2b data released September 201410/25/2014
FOMX
8.10FDX104Chemotherapy Induced RashPhase 2Phase 2 initiated Oct 201410/25/2014
FOMX
8.10FDX101RosaceaPhase 2Phase 2 to be initiated 201510/25/2014
FOMX
8.10FDX101AcnePhase 2Phase 3 to be initiated mid 201510/25/2014
FOMX
8.10FDX102ImpetigoPhase 2Phase 2 to be initiated 2H 201510/25/2014
FWP
21.82FP187Multiple sclerosisPhase 3Phase 3 planned10/25/2014
FWP
21.82FP187PsoriasisPhase 3Phase 3 planned for early 201510/25/2014
INNL
7.50CogenziaDiabetic foot ulcer infectionsPhase 3Phase 3 to be initiated 2H 2014. Data due late 201510/25/2014
OPRN
CabalettaOculopharyngeal Muscular DystrophyPhase 2/3Phase 2/3 ongoing10/25/2014
SAGE
38.25SAGE-547Essential tremorPhase 2Phase 2 initiated Oct 201410/25/2014
ALKS
69.81ALKS 9070 aripiprazole lauroxilSchizophreniaPDUFAPDUFA August 22 201510/23/2014
AGIO
123.65AG-221Cancer - advanced solid tumorsPhase 1/2Phase 1/2 initiated Oct 201410/22/2014
OMER
22.86OMER824Huntington diseasePhase 2Phase 2 initiated Feb 2014. Trial placed on hold due to preclinical concerns10/22/2014
CCXI
8.49Vercirnon CCX282 - (SHIELD-4)Crohn's diseasePhase 3Data presented Oct 201410/21/2014
MDGN
7.10Erythropoietin ("EPO") therapy delivered via EPODURE BiopumpAnemiaPhase 2Phase 1/2 trial commenced enrolment Jun 2014. Initial data released Oct 15 201410/19/2014
OHRP
7.83Squalamine Eye DropsNeovascular (Wet) Age-related Macular Degeneration (AMD)Phase 2Phase 2 interim data released June 24 2014. Final data due 1Q 2015. Phase 3 to be initiated 1H 201510/15/2014
ADHD
6.40MDX (Metadoxine Extended Release (MG01CI))Adult ADHDPhase 3Phase 3 initiated March 2014. Topline data released Oct 201410/11/2014
ARDX
26.62TenapanorConstipation-predominant irritable bowel syndrome (IBS-C) Phase 2bData released Oct 201410/11/2014
ESPR
46.31ETC-1002-008HypercholesterolemiaPhase 2bPhase 2b initiation Oct 2013. Data released October 201410/11/2014
MNTA
10.63M402Cancer - advanced metastatic pancreatic cancerPhase 1/2Initiated Phase 1/2 proof of concept trial Jul 2012. Data from Part A of trial released Oct 201410/11/2014
OXGN
1.59Fosbretabulin Combined With Pazopanib Cancer - Recurrent Ovarian CancerPhase 1/2Phase 1/2 initiated Oct 201410/11/2014
RNA
18.82DrisapersenDuchenne Muscular Dystrophy (DMD)NDA filingPhase 3 endpoint not met Sept 2013. NDA filing commenced Oct 201410/11/2014
SNSS
2.20VoreloxinCancer - Acute myeloid leukemia AMLPhase 3Endpoint not met Oct 201410/11/2014
STEM
1.05HuCNS-SC cellsSpinal cord injury Phase 1/2Interim data released May and Sept 2012. 2nd cohort dosing initiated Sept 2012.12mth data released Feb 2013. Enrolment completed April 2014. Additional Interim data due May 2014. Final data due mid 2015. Phase 2 trial initiated Oct 201410/11/2014
ZFGN
38.97BeloranibPrader-Willi Syndrome (PWS)Phase 3First of two Phase 3 trials to initiated Oct 2014. Initial data due 4Q 201510/11/2014
CYTR
2.77AldoxorubicinCancer - SCLCPhase 2bPhase 2b to be initiated Sept 201410/01/2014
PGNX
6.14Subcutaneous RELISTORchronic painApprovedApproved September 29 201410/01/2014
SLXP
125.92RELISTOR (methylnaltrexone bromide) - subcutaneous useOpioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.ApprovedApproved September 29 201410/01/2014
ACST
0.51CaPre (TRIFECTA trial)HypertriglyceridemiaPhase 2Phase 2 trial of CaPre (TRIFECTA trial) completed Sept 201409/30/2014
KERX
13.23ZerenexIron deficiency anemia in non-dialysis dependent CKD patientsPhase 3Phase 3 initiated 3Q 201409/30/2014
PBYI
212.69PB272 HER2 mutated non-small cell lung cancerPhase 2Phase 2 initial data released 201409/30/2014
SGEN
32.30ADCETRIS - AETHERACancer - post-transplant Hodgkin lymphoma (HL) patientsPhase 3Phase 3 data released Sept 29 2014, sBLA filing due 201509/30/2014
ALIM
5.53IluvienDiabetic macular edemaApprovedApproved Sept 26 201409/28/2014
GLYC
6.90GMI-1070 (rivipansel)Vaso-occlusive crisis of sickle cell diseasePhase 3Phase 3 planned 09/28/2014
PSDV
4.09IluvienDiabetic macular edemaApprovedApproved Sept 26 201409/28/2014
ZSPH
46.00ZS-9HyperkalemiaPhase 3Phase 3 endpoints met09/24/2014
DVAX
17.54HEPLISAVHepatitis BCRLCRL Feb 25 2013. Met with FDA Jun 2013. Phase 3 initiated 1Q 2014, expects that all study subjects will be enrolled by the end of 2014 and all follow-up will be completed by October 2015.09/23/2014
DYAX
15.51CYRAMZA (ramucirumab)Colorectal cancerPhase 3Filing due 1H 201509/23/2014
DYAX
15.51CYRAMZA (ramucirumab)Non-small cell lung cancer (NSCLC)BLAFiling due by end of 201409/23/2014
DYAX
15.51Necitumumab - SQUIRECancer - NSCLCBLABLA filing due by end of 201409/23/2014
DYAX
15.51Anti-LINGO - RENEW trialAcute optic neuritisPhase 2Phase 2 topline data due early 201509/23/2014
DYAX
15.51Anti-LINGO - SYNERGY trialRelapsing forms of multiple sclerosisPhase 2Phase 2 topline data due 201609/23/2014
TKMR
25.17TKM-Ebola Ebola Phase 1/2Placed on partial clinical hold but available under expanded use program09/23/2014
IMUC
0.68ICT-107 dendritic cell vaccineGlioblastoma antigens and cancer stem cellsPhase 2bPhase 2b failed to meet primary endpoint. Plans to meet FDA in 2014. Possible Phase 3 initiation mid 201509/21/2014
AUXL
35.95AvanafilErectile dysfunctionApprovedApproved Apr 27 2012. sNDA label change also approved 17 Sept 201409/18/2014
ISIS
71.28PlazomicinMulti-drug resistant (MDR)Phase 3Phase 3 initiated Sept 201409/18/2014
NVAX
7.37RSV F VaccineRespiratory Syncytial Virus (RSV) in women in their third trimester of pregnancyPhase 2Phase 2 initiated Sept 201409/18/2014
OXGN
1.59FosbretabulinCancer - gastrointestinal neuroendocrine tumorsPhase 2Phase 2 initiated Sept 201409/18/2014
VVUS
2.74AvanafilErectile dysfunctionApprovedApproved Apr 27 2012. sNDA label change also approved 17 Sept 201409/18/2014
NKTR
14.62NaloxegolOpioid-induced constipation (OIC)ApprovedApproved Sept 16 201409/17/2014
ONCY
0.47REOLYSIN - intravenous with gemcitabineCancer - PancreaticPhase 2Data released Aug 201409/17/2014
AMRN
1.03Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed DyslipidemiaREDUCE-IT outcomes trialREDUCE-IT outcomes trial data due 201809/16/2014
AVNR
16.96NUEDEXTA AVP-923Agitation in patients with Alzheimer's disease (AD)Phase 2Phase 2 data released September 201409/16/2014
SLXP
125.92Budesonide foamModerate ulcerative proctitis or proctosigmoiditis ApprovedTentative approval granted September 15 2014 pending patent issues09/16/2014
HALO
13.87HYQVIASubcutaneous treatment for patients with primary immunodeficiency (PI)ApprovedApproved Sept 12 201409/14/2014
ENTA
44.92ABT-493HCV Phase 2bPhase 2b initiated Sept 2014. Data due 2015.09/11/2014
MDVN
106.27XTANDICancer - mCRPC who have not received chemotherapyApprovedApproved Sept 10 201409/11/2014
OREX
5.41ContraveObesityApprovedApproved September 11 201409/11/2014
PTN
0.70PL-3994Heart failurePhase 2aPhase 2a to be initiated 1H 201509/10/2014
SPPI
6.77SPI-2012 (also referred to as "LAPS-GCSF")Chemotherapy-Induced NeutropeniaPhase 2Phase 3 to be initiated in 201509/10/2014
HPTX
24.95 DiaPep277Type 1 diabetesPhase 3Trial stopped due to employee misconduct09/09/2014
MSTX
0.47AIR001 Pulmonary Hypertension Phase 2Phase 2 prelim data released Sept 201409/09/2014
KERX
13.23ZerenexHyperphosphatemiaApprovedApproved Sept 5 201409/07/2014
CLSN
2.21ThermoDoxCancer - Hepatocellular carcinoma - liver cancerPhase 3Failed to meet primary endpoint. New Phase 3 be initiated Sept 201409/03/2014
SLXP
125.92XIFAXANIrritable bowel syndrome with diarrhea (IBS-D)NDAFiled response to CRL Aug 29 201409/03/2014
ISIS
71.28ISIS-APOCIIIRxFamilial chylomicronemia syndrome (FCS)Phase 3Phase 3 initiated Aug 201408/29/2014
LGND
54.67PromactaAplastic AnemiaApprovedApproved August 27 201408/28/2014
CNCE
#N/AAVP-786 Neurologic and Psychiatric DisordersPhase 2Phase 2 initiated August 201408/27/2014
RGDO
1.06REGULATE-PCI - REG1percutaneous coronary intervention (PCI)Phase 3Trial halted due to safety concerns - Aug 201408/26/2014
AUXL
35.95XIAFLEXEdematous fibrosclerotic panniculopathy (“cellulite”)Phase 2aPhase 2b to commence 2Q 201508/22/2014
OGXI
2.09Custirsen ENSPIRITCancer - NSCLCPhase 3Phase 3 initiated Oct 2012. First interim analysis released August 2014. Trial to continue as planned.08/22/2014
NBY
0.60Auriclosene (NVC-422)Viral conjunctivitisPhase 2bData released August 2014. Endpoints not met08/21/2014
MNOV
3.54MN-166Opioid dependence Phase 2Phase 2 interim data released August 201408/19/2014
ALDR
8.94Clazakizumab Rheumatoid arthritis (RA)Phase 2bPhase 2b to be completed 1H 201508/17/2014
ARRY
7.11Selumetinib (AZD6244) combined with radioactive iodine - ASTRACancer - differentiated thyroid cancer Phase 3Pivotal trial initiated August 2013. The estimated primary completion date for the ASTRA study is June 201608/17/2014
ARRY
7.11Selumetinib (AZD6244) in Combination With DocetaxelCancer - NSCLC second line non small lung cancerPhase 3Phase 3 initiated Oct 2013. The estimated primary completion date for the SELECT-1 study is July 201608/17/2014
ISIS
71.28ISIS-CRPRx (ASET)Atrial fibrillationPhase 2Initiated Feb 2013. Data released 201408/17/2014
NWBO
6.28DCVaxCancer - Glioblastoma multiforme (GBM) brain cancerPhase 3First trigger for interim analysis hit. Topline data due 1H 2015 as per Jan 2014 conference. However, trial design was altered in Aug 2014. No timeline update in PR08/17/2014
TKMR
25.17ALN-TTR02 - patisiranFamilial Amyloidotic Polyneuropathy (FAP) in Patients with ATTRPhase 2 - open labelPhase 2 enrolment completed Sept 2013. Initial data due October 2014. Partnered with ALNY08/17/2014
ARRY
7.11ARRY 797LMNA-Related DCMPhase 2Phase 2 preliminary results from this study due by the end of 2014.08/16/2014
ARRY
7.11ARRY-520 (Filanesib)Cancer - Refractory Multiple Myeloma MMPhase 2Phase 3 to be initiated 2H 201408/16/2014
CEMP
25.49CEM-101 (solithromycin )Uncomplicated urogenital gonococcal infectionsPhase 3Phase 3 initiated August 201408/16/2014
EXAS
27.16CologuardCancer - Colorectal DNA testApprovedApproved August 201408/16/2014
FPRX
24.95FP-1039FGFR1Phase 1bPhase 1b initiated July 2013. Prelim data due by end of 201408/16/2014
RNA
18.82 PRO053DMDPhase 1/2Phase 1/2 initiated Jun 2013. Data due 1H 201508/16/2014
RNA
18.82PRO044Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 44 in the DNA for the dystrophin proteinPlacebo trial to commence 201508/16/2014
RTGN
3.99RUT58-60Prevention of infection post abdominal surgeryPhase 1/2Phase 1/2 to be completed 1Q 201508/16/2014
ARGS
7.72AGS-003 Early stage RCC, non-clear cell mRCC, and other solid tumorsPhase 2Phase 2 trials planned for 201408/14/2014
MACK
9.59MM-302 HERMIONECancer - HER2-positive locally advanced or metastatic breast cancerPhase 2Phase 2 initiated August 201408/14/2014
APPY
1.93Appy1Acute appendicitis Phase 3Data released Mar 13 2014. 510k filed March 2014. Supplemental filling due 4Q 201408/12/2014
NRX
8.25PyridorinDiabetic nephropathyPhase 3Phase 3 initiated June 2014. Enrolment due to be half complete by 1Q 201508/12/2014
BLRX
1.83BL-8040Chronic Myeloid Leukemia Phase 1/2Phase 1/2 to be initiated late 201408/10/2014
CLDX
22.75CDX-110 rindopepimut - ACT IVCancer- glioblastoma multiforme (GBM) front linePhase 3Initiated Phase 3 Dec 2011. Aim to complete screening by September 201408/10/2014
MDCO
28.40OritavancinABSSSIPDUFAApproved August 6 2014 under priority review08/10/2014
OXGN
1.59ZYBRESTATCancer - OvarianPhase 2Met primary endpoint March 2014. Further data to be presented at the International Gynecologic Cancer Society meeting from November 8 201408/10/2014
RVX
20.80RVX-208 Pre-diabetes mellitus Phase 2Phase 2 initiated Oct 2012, data released mid 201408/10/2014
SNTA
2.47Ganetespib AML-18 trialCancer - AMLPhase 2/3Expect to initiated in 2H 201408/10/2014
SNTA
2.47Ganetespib AML-19 trialCancer - AMLPhase 2/3Phase 3 to be initiated 2H 201408/10/2014
DRRX
0.91ORADUR-HydromorphoneORADUR-HydromorphonePhase 3Phase 3 to be initiated 201508/09/2014
DRRX
0.91ReldayPhase 3Phase 3 to be initiated by ZGNX in 4Q 201408/09/2014
INFI
15.29Duvelisib (IPI-145)Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)Phase 3Phase 3 enrolment to be completed 2H 201508/09/2014
PTIE
1.95ORADUR-HydromorphonePhase 3Phase 3 to be initiated 201508/09/2014
ISIS
71.28ISIS-GCCRRx Type 2 diabetesPhase 2Phase 2 data due 201408/05/2014
ISIS
71.28ISIS-PTP1BRxType 2 diabetesPhase 2Phase 2 data due 201408/05/2014
ADMP
5.99Epinephrine PFSAnaphylaxisPDUFAPDUFA estimate on or around May 29 2015. No official date given08/03/2014
BOTA
2.41Laninamivir Octanoate - IGLOO Adults with symptomatic influenza A or B infectionPhase 2Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 201408/03/2014
CVM
0.65MultiklineCancer - Head and NeckPhase 3Initiated Dec 2010, enrolling. 117 patients enrolled as of Apr 2013. 146 patients as of Feb 2014. Full enrolment due to be completed by end of 201508/03/2014
DYAX
15.51CYRAMZA (ramucirumab)Gastric CancerApprovedApproved April 201408/03/2014
DYAX
15.51Trebananib (AMG 386)OvarianPhase 3Met endpoint08/03/2014
EDAP
2.78 Ablatherm-HIFU (High Intensity Focused Ultrasound) Cancer - Low risk, localized prostate cancerPMAPMA submitted Feb 2013. Adcom negative vote July 30 201408/03/2014
IMGN
6.33Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla KRISTINE trialCancer - neo-adjuvant settingPhase 3Phase 3 enrolling08/03/2014
INCY
79.90INCB39110Non-small cell lung cancerPhase 2Phase 2 underway - July 201408/03/2014
PCRX
106.54EXPARELSingle-dose injection femoral nerve block for total knee arthroplasty surgeryPDUFAPDUFA March 5 2015.08/03/2014
PCYC
158.55IMBRUVICACancer - relapsed/refractory multiple myeloma (MM)Phase 1/2bOngoing08/03/2014
PCYC
158.55IMBRUVICA RESONATECancer - Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL)ApprovedApproved July 29 201408/03/2014
PCYC
158.55IMBRUVICAMarginal Zone Lymphoma (MZL)Phase 2Phase 2 initiated 4Q 201308/03/2014
SGEN
32.30ADCETRISCancer - for front-line treatment of elderly patients with HLPhase 2Initiated Phase 2 Oct 2012. Data due 201408/03/2014
VICL
1.04ASP0113Hematopoietic cell transplantPhase 3Initiated Phase 3 Jun 2013. Still enrolling as of August 201408/03/2014
VICL
1.04ASP0113solid organ transplant (SOT)Phase 2Initiated Phase 2 Dec 2013. Still enrolling as of August 201408/03/2014
ALXN
183.32Asfotase alfaHypophosphatasia (HPP)BLARolling BLA filing ongoing07/27/2014
CLSN
2.21ThermoDoxRecurrent Chest Wall Breast Cancer (RCWBC)Phase 2Phase 2 interim data released Feb and July 201407/27/2014
LPTN
2.96ASONEPRenal cell carcinoma (RCC)Phase 2aPhase 2a initiated dosing May 23 2013. Interim data reported July 201407/27/2014
EGRX
18.92RyanodexMalignant hyperthermiaApprovedApproved July 22, 2014 under priority review07/24/2014
INCY
79.90Jakafi (ruxolitinib) (RELIEF)Disease-related symptoms in patients with Polycythemia VeraPhase 3Endpoint not met, mid-201407/24/2014
RXDX
6.86RXDX-101Cancer - solid tumorsPhase 1/2Phase 1/2 trial initiated July 201407/22/2014
SNTA
2.47Ganetespib AML-LI trialCancer - AMLPhase 2/3Phase 3 part of trial initiated mid-201407/22/2014
TKMR
25.17TKM-PLK1Adrenocortical Carcinoma (ACC)Phase 1/2Enrolling as of June 2014. Interim data due 2H 201407/22/2014
ISIS
71.28ISIS-APO(a)RxHigh lipoprotein(a), or Lp(a)Phase 2Phase 2 initiated July 201407/18/2014
NWBO
6.28DCVaxCancer - inoperable solid tumor cancersPhase 1/2Initial data released May 2014. Phase 2 portion planned07/17/2014
SLXP
125.92RUCONESTHereditary angioedema (HAE)ApprovedApproved July 16, 201407/17/2014
ANTH
2.08Sollpura (liprotamase)Exocrine Pancreatic InsufficiencyPhase 3Phase 3 due to be initiated mid 201507/15/2014
ANAC
34.15TavaboroleOnychomycosisApprovedApproved July 8 201407/09/2014
GBIM
6.74GS-4774Chronic hepatitis B infectionPhase 2Phase 2 initiated by GILD Sept 201307/09/2014
GBIM
6.74GI-6207Medullary thyroid cancerPhase 2Phase 2 ongoing07/09/2014
GBIM
6.74GI-4000Cancer - Non-small cell lung cancerPhase 2Phase 2b planned07/09/2014
GBIM
6.74GI-4000Cancer - colorectal cancer Phase 2Phase 2a ongoing07/09/2014
KITE
67.37KTE-C19Relapsed/refractory diffuse large B cell lymphoma, or DLBCLPhase 1/2Phase 1/2 planned for 201507/09/2014
ONCY
0.47REOLYSIN in Combination with Paclitaxel and CarboplatinCancer - Metastatic Pancreatic CancerPhase 2Enrolment completed July 201407/09/2014
RDUS
38.65RAD1901 Vasomotor symptoms such as hot flashesPhase 2Phase 2 complete07/09/2014
RDUS
38.65Abaloparatide-TD (patch)OsteoporosisPhase 2Phase 2 complete07/09/2014
ZFGN
38.97BeloranibCraniopharyngioma-associated obesityPhase 2aPhase 2a initiated June 201407/09/2014
CRME
10.03Vernakalant IV Atrial fibrillationPhase 3Phase 3 placed on clinical hold Oct 2010 due to patient death07/07/2014
TKMR
25.17ALN-TTR02 - patisiran APOLLOFamilial Amyloidotic Polyneuropathy (FAP) in Patients with ATTRPhase 3Phase 3 trial initiated Nov 2013, continues to enrol patients as of Jan 2014. Partnered with ALNY07/07/2014
SPPI
6.77BelinostatCancer - Peripheral T-Cell LymphomaApprovedApproved July 3 201407/04/2014
EGRX
18.92EP-3101 (bendamustine RTD) Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphomaApproved (tentative)Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively. 07/03/2014
OGXI
2.09OGX-427 plus gemcitabine and carboplatin - Cedar TrialNon-squamous, non-small cell lung cancer (NSCLC)Phase 2Phase 2 open label initiated July 201407/02/2014
THLD
3.52TH-302Cancer - second line NSCLCPhase 2Phase 2 initiated July 201407/02/2014
FLML
14.48VAZCULEP (phenylephrine hydrochloride)Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesiaApprovedApproved June 30 201407/01/2014
NPSP
45.64GATTEXShort Bowel Syndrome - seeking additions to labelApprovedApproved June 201407/01/2014
PBYI
212.69PB272Third line HER2+ MBC Phase 3Phase 3 initiated June 201307/01/2014
MNKD
5.75AFREZZA Type 1/2 diabetesApprovedApproved June 27 201406/28/2014
KPTI
27.66SelinexorCancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)Phase 2Phase 2 initiated June 25 201406/25/2014
CBST
101.94Tedizolid phosphateAcute bacterial skin and skin structure infections (ABSSSI)ApprovedApproved June 20 201406/22/2014
MACK
9.59MM-121 Cancer - triple negative breast cancer cohort in the neoadjuvant settingPhase 2Phase 2 data released June 201406/22/2014
OPK
10.84hGH-CTPChildren - growth hormone deficiencyPhase 3CC to discuss Phase 2 data Jun 23 2014 - Phase 3 data due 1H 2018 (yet to be initiated)06/22/2014
CLVS
64.74Rucaparib RUCAPANCCancer - pancreaticPhase 2Phase 2 initiated June 201406/17/2014
NAVB
1.72LymphoseekHead and Neck CancerApprovedApproved Jun 13 201406/14/2014
ACHN
15.99SovaprevirHepatitis C viral infection (HCV)Phase 2Placed on clinical hold Jul 2013.Clinical hold lifted June 201406/11/2014
KPTI
27.66SelinexorCancer - hormone-refractory prostate cancer (HRPC)Phase 2Phase 2 initiated June 201406/10/2014
BDSI
12.71BEMA Buprenorphine/Naloxone (BNX) - BUNAVAILOpioid dependenceApprovedApproved June 7 201406/08/2014
ALKS
69.81ALKS 3831SchizophreniaPhase 2Second Phase 2 trial initiated June 2014. Data due mid 201706/03/2014
INCY
79.90INCB24360 in combination with ipilimumabCancer - MelanomaPhase 1/2Prelim data released at ASCo 201406/03/2014
OMER
22.86OmidriaCataract surgeryApprovedApproved June 2 201406/03/2014
ARIA
6.10PonatinibGastrointestinal stromal tumors (GIST)Phase 2Enrolment paused Oct 2013 due to safety issues. Initial data released at ASCO 2014. Trial resumed 2Q 201406/02/2014
NKTR
14.62Etirinotecan pegol NKTR-102Cancer - gliomaPhase 2Phase 2 data released at ASCO 201406/02/2014
TRLPF
0.58CompleoTRTTestosterone deficiency in menApprovedApproved May 201405/29/2014
QRXPY
0.10MOXDUOModerate to severe acute painCRLCRL Aug 2013. New PDUFA May 25 2014. New CRL May 27 201405/28/2014
ISIS
71.28ISIS-FXIRxClotting disorders in patients undergoing knee replacement surgeryPhase 2Phase 2 data released May 201405/24/2014
MDWD
7.74EscharEx Chronic and other hard-to-heal woundsPhase 2Phase 2 data due 2H 2015 (Israel)05/24/2014
CORI
7.26MicroCor hPTH(1-34) OsteoporosisPhase 2Phase 2 planned for 201405/17/2014
IDRA
4.51 IM0-8400 DLBCL who harbor the MYD88 L265P mutationPhase 1/2Phase 1/2 to be initiated 2H 201405/17/2014
KMDA
3.91Inhaled formulation of AATAATD - Alpha-1 Antitrypsin deficiencyPhase 2/3Top-line data from the pivotal Phase 2/3 clinical trial did not meet primary endpoint - May 201405/17/2014
OPHT
55.52ZimuraGeographic atrophyPhase 2/3Phase 2/3 trial to be initiated late 201405/17/2014
OPHT
55.52Fovista and ZimuraWet AMDPhase 2/3Phase 2 trial to be initiated 201505/17/2014
RTRX
13.47Sparsentan (DUET) Focal segmental glomerulosclerosis (FSGS)Phase 2/3Enrolment due to be completed late 2014 or early 201505/17/2014
RTRX
13.47RE-034 Infantile Spasms and Membranous NephropathyPhase 3Phase 3 to be initiated 3Q 201405/17/2014
TTHI
6.83TT-401Type 2 diabetesPhase 2Phase 2 initiated May 201405/17/2014
GTXI
0.62Ostarine (Enobosarm (GTx-024))ER Positive Metastatic Breast CancerPhase 2Phase 2 initiated Apr 2013. Enrolling. Prelim Data due late 2Q 2014 at ASCO05/12/2014
LXRX
0.92LX1032 Telotristat etiprateCarcinoid SyndromePhase 3Phase 3 initiated Sep 2012. Enrolment due to be completed by end of 201405/12/2014
ZIOP
7.24IL-12Cancer - breastPhase 2Updated data released at AACR Tumor Immunology and Immunotherapy Meeting December 201405/12/2014
ZIOP
7.24IL-12Cancer - melanomaPhase 2Updated data released at AACR Tumor Immunology and Immunotherapy Meeting December 2,01405/12/2014
GALE
1.66NeuVax in combination with HerceptinBreast cancerPhase 2bPhase 2b ongoing05/11/2014
KBIO
0.44Pa ventilator associated pneumonia (VAP)Phase 2bPhase 2b trial to be initiated mid 201505/11/2014
MDVN
106.27Enzalutamide Androgen receptor positive, triple-negative breast cancerPhase 2Phase 2 initiated June 2013. Enrolment continues as of May 201405/11/2014
MDVN
106.27EnzalutamideAdvanced Breast Cancer That Is Estrogen or Progesterone Receptor Positive and HER2 NormalPhase 2Phase 2 initiated Dec 2013. Enrolment continues as of May 201405/11/2014
MDVN
106.27MDV3100 cf Bicalutamide STRIVE trialCancer - prostate enrolling both metastatic and non-metastatic patientsPhase 2Completed enrolment March 201405/11/2014
MDVN
106.27 Enzalutamide PROSPERNon-Metastatic Castration-Resistant Prostate CancerPhase 3Phase 3 initiated Nov 2013. Enrolment ongoing as of May 201405/11/2014
OHRP
7.83OHR-005Diabetic macular edema (DME)Phase 2Phase 2 initiated May 201405/10/2014
ACOR
43.76Diazepam Nasal SprayEpilepsyCRLCRL issued May 201405/04/2014
ECYT
5.13vintafolideCancer - ovarianPhase 3Trial stopped due to poor efficacy05/04/2014
MACK
9.59MM-151CancerPhase 2Phase 2 to be initiated 201405/04/2014
FOLD
8.31migalastat HCl monotherapy (011)Fabry DiseasePhase 3 6 month data released Dec 2012 did not show statistical significance. 12/24 month data released April 201405/01/2014
IRWD
15.98IW-9179Functional dyspepsiaPhase 2aEnded trial prior to completing enrolment due to various issues05/01/2014
KPTI
27.66SelinexorCancer - glioblastoma following treatment with radiation and temozolomide.Phase 2Phase 2 initiated April 201405/01/2014
MDCO
28.40CangrelorReduction of thrombotic cardiovascular events including stent thrombosis (events related to blood clots in a stent, a device inserted to keep the artery open) in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).CRLAdcom meeting Feb 12 2014 recommended against approval. CRL April 30 201405/01/2014
NYMX
0.42NX-1207Cancer - low grade localized prostatePhase 2Phase 2 data released April 201405/01/2014
RXII
1.17 (RXI-109-1401)Recurrence of keloids after keloid revision surgeryPhase 2Phase 2 initiated April 201405/01/2014
SYN
1.53Trimesta ( oral estriol)Relapsing-remitting MS in womenPhase 2Phase 2 data released Apr 201405/01/2014
THRX
11.78TD-9855FibromyalgiaPhase 2Phase 2 data released April 201405/01/2014
NVAX
7.37RSV vaccineRespiratory Syncytial Virus (RSV) in women of childbearing age.Phase 2Phase 2 topline data released April 201404/29/2014
PBMD
0.80CAN-004Cancer - ovarianPhase 2Phase 2 commenced April 201404/29/2014
KBIO
0.44KB004MDS and AMLPhase 2Phase 2 initiated Feb 2014. Top-line Data due 2Q or 3Q 201504/27/2014
NKTR
14.62Inhaled Amikacin Solution (BAY41-6551T)Gram-Negative Pneumonia (INHALE 1)Phase 3Phase 3 data due 1H 201504/27/2014
SSH
4.88C-Pulse Heart Assist System - COUNTER HFModerate to severe heart failurePivotal Expects to complete enrolment 1H 201604/27/2014
SSH
4.88C-Pulse Heart Assist System - OPTIONS HF study Moderate to severe heart failureData due mid 201504/27/2014
ADMS
17.01Amantadine Traumatic Brain InjuryPhase 2/3 Phase 2/3 planned for 201404/25/2014
ADMS
17.01AmantadineUnknownPhase 2/3Phase 2/3 planned for 201504/25/2014
CERU
8.25CRLX101 and XelodaNeoadjuvant Rectal CancerPhase 1b/2Ongoing04/25/2014
CORI
7.26AG200-15ContraceptivePhase 3Additional Phase 3 planned following rejection of NDA04/25/2014
CORI
7.26Corplex Tamsulosin Benign prostatic hyperplasiaPhase 2Phase 2 planned 1H 201504/25/2014
IDRA
4.51IMO-8400PsoriasisPhase 2Phase 2 initiated Jun 2013. Data released Mar 201404/25/2014
KPTI
27.66SelinexorCancer - Advanced Gynecologic Malignancies (SIGN Study)Phase 2Phase 2 initiated April 201404/25/2014
MDWD
7.74NexoBridSevere burnsPhase 3Phase 3 planned 1H 201404/25/2014
RXII
1.17RXI-109-1402Suppressing recurrence of hypertrophic scars after bilateral scar revision surgery in the breast areaPhase 2Phase 2 initiated July 201404/25/2014
FLXN
21.78FX007Phase 2Phase 2 trial to be initiated 201404/24/2014
TLOG
5.83BirinapantCancer - acute myelogenous leukemia or AMLPhase 1/2Ongoing04/23/2014
XNCR
17.41MOR208 (XmAb5574)B-cell acute lymphoblastic leukemia (B-ALL) Phase 2Phase 2 initiated 2Q 201304/23/2014
XNCR
17.41MOR208 (XmAb5574)Non-Hodgkin lymphoma (NHL)Phase 2Phase 2 initiated 2Q 201304/23/2014
RNN
0.71ArchexinCancer - metastatic renal cell carcinoma (RCC)Phase 2Phase 2 initiation Jan 2014. Initial phase to be completed late 201404/11/2014
THRX
11.78TD-4208Chronic obstructive pulmonary disease (COPDPhase 2bPhase 2b data released Sept 2013. Dose ranging Phase 2b trial initiated April 2014 04/11/2014
ASMB
8.54VEN 307 (diltiazem cream)Anal fissuresPhase 3Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Type B pre-NDA meeting on Thursday, June 19, 201404/10/2014
ONCY
0.47 REOLYSIN with paclitaxel & carboplatinCancer - Head and NeckPhase 2Data released Apr 2014. Phase 3 planned04/10/2014
MDCO
28.40FibrocapsHemostasisPDUFAPDUFA January 31, 2015.04/04/2014
PRAN
1.40PBT-2Alzheimer'sPhase 2Phase 2 endpoint not met04/01/2014
HALO
13.87HTI-501CelluoitePhase 2Phase 2 data due released Jul 2013. Topline data released 1Q 201403/26/2014
ECYT
5.13Vintafolide (TARGET)Cancer - NSCLCPhase 2bPhase 2b topline data released March 2014. Endpoint met.03/23/2014
SNTA
2.47Ganetespib ENCHANT trialCancer - HER2+ and triple-negative breast cancerPhase 2Update provided March 201403/23/2014
GALE
1.66GALE 301 -Folate Binding Protein (FBP) vaccineEndometrial and ovarian cancerPhase 2Phase 2 initiated Jan 2014. Enrolment completed June 2014. Data due mid 201503/18/2014
MDCO
28.40IONSYSAcute postoperative painsNDAsNDA to be filed 1H 201403/18/2014
IMUC
0.68ICT-140Recurrent ovarian cancerPhase 2aPhase 2 planned for 3Q 201403/15/2014
NLNK
39.40HyperAcute LungCancer - NSCLCPhase 2b/3Initiated Phase 2b/3 Oct 2012, ongoing as of March 201403/12/2014
NLNK
39.40HyperAcute Melanoma - dorgenmeltucel-LCancer - melanomaPhase 1b/2Planning03/12/2014
NLNK
39.40Indoximod in combination with docetaxelCancer - breastPhase 2Phase 2 initiated Apr 2013. Ongoing as of March 201403/12/2014
NLNK
39.40Sipuleucel-T (PROVENGE®) plus indoximod (D-1MT/NLG8189) Asymptomatic or minimally symptomatic metastatic hormone refractory prostate cancerriglPhase 2Phase 2 initiated Sep 2012. Ongoing as of March 201403/12/2014
SNSS
2.20Vosaroxin in combination with decitabineOlder patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)Phase 2Phase 2 updated due at American Association for Cancer Research Annual Meeting 2014 (AACR) on April 803/07/2014
BLUE
95.92Lenti-DChildhood cerebral adrenoleukodystrophy (CCALD)Phase 2/3Phase 2/3 trial initiated October 2013. Enrolment due to be completed 201503/06/2014
KMDA
3.91GlassiaPediatric patients newly diagnosed with type 1 diabetesPhase 2/3Phase 2/3 initiated Mar 201403/06/2014
XOMA
3.48XOMA 052 GevokizumabErosive osteoarthritis of the handPhase 2Phase 2 prelim data released Oct 2013. Not pursuing futre development03/06/2014
ARRY
7.11ARRY 502Asthma Phase 2aPhase 2 topline data released July 23 2013. Endpoint met. Full data released Mar 201403/04/2014
CLDX
22.75CDX-011 EMERGECancer - Metastatic breastPhase 2bPrelim data released May 23 2012. Updated data released Dec 2012. Phase 3 trial initiated Dec 201303/04/2014
CLVS
64.74Rucaparib ARIEL3 Cancer - ovarian second linePivotalPivotal trial initiated late 201302/28/2014
SCMP
15.18CobiprostoneOral MucositisPhase 1b/2aPhase 1b/2a initiated 4Q 201302/27/2014
XLRN
39.24DalanterceptHead and neck cancerPhase 2Phase 2 interim data due at ASCO 201402/27/2014
XLRN
39.24DalanterceptLiver cancerPhase 2aPhase 2a to be initiated 1Q or 2Q 201402/27/2014
AUXL
35.95XIAFLEXDupuytren's ContracturePDUFAPDUFA Date Scheduled for October 20, 201402/25/2014
ECYT
5.13vintafolideCancer - folate receptor-positive triple negative breast cancerPhase 2Initiate Phase 2 2Q 201402/25/2014
PCYC
158.55IMBRUVICA in combination with bendamustine and rituximab - SHINE (MCL3002)Cancer - newly diagnosed MCLPhase 3Janssen plans to enroll 520 patients02/21/2014
PCYC
158.55IMBRUVICAR/R CLL/SLLPhase 3Phase 3 initiated 4Q 201302/21/2014
RPTP
9.29DR CysteamineHuntington's DiseasePhase 2Topline Phase 2/3 data released Feb 2014 02/21/2014
PRAN
1.40PBT-2Huntington's DiseasePhase 2Data released Feb 201402/19/2014
ANIK
39.60MonoviscOsteoarthritisApprovedApproved Feb 201402/16/2014
BMRN
97.69Vimizim (GALNS)(MPS IVA) Morquio A SyndromeApprovedApproved Feb 14 201402/16/2014
DRRX
0.91PosidurPost-operative pain relief CRLCRL Feb 12 201402/13/2014
INCY
79.90BaricitinibDiabetic nephropathyPhase 2Phase 2 initiated Aug 2012. Data due 201502/13/2014
INCY
79.90INCB24360Cancer - OvarianPhase 2Ongoing02/13/2014
PCYC
158.55IMBRUVICA Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior TherapyApprovedApproved Feb 12 201402/13/2014
NAVB
1.72NAV4694Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)Phase 2Phase 2 initiated Mar 2013. Initial data released Feb 2014. Data due 4Q 2016. 02/07/2014
THRX
11.78Velusetragdiabetic or idiopathic gastroparesisPhase 2Phase 2 data due 1H 201402/07/2014
ARRY
7.11Selumetinib (AZD6244) + plus dacarbazine SUMITCancer - metastatic uveal melanoma Phase 3Phase 3 estimated primary completion date for the trial is mid-201502/05/2014
ADMP
5.99APC-3000Allergic RhinitisPhase 3Phase 3 planned02/04/2014
ADMP
5.99APC-1000Asthma/COPDPhase 3Phase 3 planned02/04/2014
IMGN
6.33SAR3419Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients (STARLYTE)Phase 2Ongoing02/02/2014
IMGN
6.33SAR3419Acute Lymphoblastic Leukemia (MYRALL)Phase 2Ongoing02/02/2014
VNDA
12.23TasimelteonInsomniaApprovedApproved Jan 31 2014. 02/02/2014
OMER
22.86OMER824SchizophreniaPhase 2Phase 2 initiated Sept 2013. Data released Jan 201401/30/2014
CTIC
2.19OpaxioCancer - OvarianPhase 3Enrolment completed Jan 201401/29/2014
MDVN
106.27MDV3100 enzalutamide PREVAILCancer - advanced prostate cancer who have not previously been treated with chemotherapyPhase 3Endpoints met October 2013. Final results released Jan 201401/29/2014
PGNX
6.14PSMA ADCCancer - metastatic castrate resistant prostate cancer (mCRPC).Phase 2Abstract released at American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium Meeting in San Francisco in January 28 2014.01/29/2014
BDSI
12.71BEMA BuprenorphineModerate to severe chronic pain in opioid naive subjectsPhase 3Phase 3 data released Jan 201401/24/2014
AMAG
46.76FerahemeIron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) to all adult patients with IDA who have failed or could not tolerate oral iron treatmentCRLCRL issued May 22 201401/23/2014
BLRX
1.83BL-5010P Non-surgical removal of benign skin lesions.PivotalCE Mark registration trial for BL-5010P expected to begin 1H 2014; results expected 2H 201401/22/2014
PSTI
2.68PLX-PAD Muscle injuryPhase 1/2Phase 1/2 data released Jan 21 201401/22/2014
THRX
11.78TD-9855Attention deficit/hyperactivity disorder (ADHD)Phase 2Phase 2 endpoint not met Nov 201301/17/2014
MNOV
3.54MN-001NASH (nonalcoholic steatohepatitis)Phase 2Phase 2 planned01/15/2014
CRIS
1.67CUDC-427Advanced and refractory solid tumors or lymphomasPhase 1Placed on partial clinical hold due to death of patient. Submission to FDA due shortly as of Jan 201401/14/2014
CUR
3.12NSI-566Motor deficits due to ischemic strokePhase 1/2Phase 1/2 trial initiated in China Aug/Sep 2013. First patient dosed Jan 201401/14/2014
HALO
13.87PEGPH20 in combination with modified FOLFIRINOX chemotherapy (mFOLFIRINOX)Cancer - pancreaticPhase 1/2Phase 1/2 initiated Oct 201301/14/2014
SCMP
15.18SPI-017Management of symptoms associated with severe lumbar spinal stenosis.Phase 2aCompleted Phase 2a Dec 2013. Additional Phase 2a trials planned for late 201401/14/2014
ICPT
165.76Obeticholic acid (OCA)Portal hypertensionPhase 2Phase 2b to be initiated 2H 201401/10/2014
ICPT
165.76Obeticholic acid (OCA) - OBADIAH1Primary bile acid diarrhea (PBAD)Phase 2Phase 2b to be initiated 2H 201401/10/2014
ABIO
0.70GencaroChronic Heart FailurePhase 2b/3Phase 2b/3 to begin enrolment 1Q 201401/09/2014
PPHM
1.33BavituximabCancer - Refractory NSCLCPhase 3Interim data released Sept 2012 reported to be faulty. Phase 3 SUNRISE trial initiated Dec 201312/31/2013
OHRP
7.83OHR/AVR118Cancer cachexia.Phase 2Phase 2 data presented Dec 201312/27/2013
ARIA
6.10Oral ponatinib - IclusigCancer - chronic myeloid leukemia, acute lymphoblastic leukemiaApproved. Marketing to resume under restricitons following earlier suspensionApproved. Marketing to resume under restricitons following earlier suspension12/21/2013
UTHR
145.30Oral treprostinilPulmonary arterial hypertension (PAH)ApprovedApproved Dec 20 201312/21/2013
NBY
0.60Auriclosene (NVC-422)Impetigo skin infection studyPhase 2bFailed to meet endpoint Nov 2013. Plans to reinitiate trial in 201412/20/2013
THRX
11.78UMEC/VI (62.5/25mcg and 125/25mcg doses) ANORO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)ApprovedApproved Dec 18 201312/19/2013
SCMP
15.18LubiprostonePediatric functional constipationPhase 3Phase 3 initiated Dec 2013, with data due early 201612/18/2013
AMPE
4.73ZertanePremature ejaculationPhase 3Pivotal trial pending. Will spin off Zertane into a standalone company called Vyrix Pharmaceuticals, Inc12/15/2013
ENZY
7.06VayarolHypertriglyceridemiaPhase 2Phase 3 planned12/15/2013
IMMU
4.73Epratuzumab (EMBODY 1)LupusPhase 3Data due 1Q 201512/14/2013
IMMU
4.73VeltuzumabCancer - immune thrombocytopenic purpura - ITPPhase 2Updated Phase 1/2 data presented at ASH Dec 201312/10/2013
AUXL
35.95XIAFLEXPeyronie’sApprovedApproved Dec 6 201312/08/2013
NAVB
1.72NAV5001 Imaging Agent for Parkinson’s DiseasePhase 3Phase 3 initiated Dec 201312/08/2013
CTIC
2.19OpaxioCancer - glioblastoma multiformePhase 2Ongoing12/07/2013
CTIC
2.19OpaxioCancer - head and neck cancerPhase 1/2Ongoing12/07/2013
SGMO
13.41SB-728-902HIV/AIDSPhase 2Data presented Dec 201312/07/2013
SGMO
13.41SB-728-1101HIV/AIDSPhase 2Data presented Dec 201312/07/2013
IDRA
4.51IMO-8400Waldenström’s MacroglobulinemiaPhase 1/2Phase 1/2 enrolment initiated Dec 201312/05/2013
CCXI
8.49CCX168Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Phase 2Data released December 201312/04/2013
EXEL
1.63Cabozantinib Plus AbirateroneChemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate CancerPhase 2Phase 2 initiated Dec 201312/03/2013
MACK
9.59MM-121 Cancer -hormone receptor positive breast cancerPhase 2Data released Nov 201311/27/2013
ACAD
31.88PimavanserinAlzheimer'sPhase 2Phase 2 initiated November 201311/15/2013
MACK
9.59MM-121Cancer - NSCLCPhase 2Endpoint not met Nov 201311/09/2013
OGXI
2.09OGX-427 with PrednisoneCancer - chemotherapy-naive patients with metastatic CRPCPhase 2Phase 2 ongoing11/09/2013
ARRY
7.11MEK162 (ARRY-162) - COLUMBUSCancer - BRAF mutant melanomaPhase 3Phase 3 initiated 2H 201311/02/2013
CASI
1.68ENMD-2076Cancer - Ovarian Clear Cell CarcinomasPhase 2Phase 2 initiated Oct 2013. 11/02/2013
MACK
9.59MM-121Cancer - ovarianPhase 2Missed endpoint Oct 201311/02/2013
SNSS
2.20VoreloxinAdult patients with previously treated intermediate-2 or high-risk myelodysplastic syndrome (MDS)Phase 1/2Phase 1/2 initiated Oct 201310/29/2013
AGEN
4.96G-100 HSPPC-96 Vaccine Cancer - Glioblastoma (GBM) first linePhase 2Prelim data released May 1 2013. Plans to meet with FDA later in an End of Phase 2 trial 10/26/2013
ZGNX
1.28Zohydro ERModerate to severe painApprovedApproved Oct 25 201310/26/2013
NKTR
14.62Etirinotecan pegol NKTR-102Cancer - relapsed or refractory Small-Cell Lung Cancer (SCLC)Phase 2Phase 2 initiated Oct 201310/25/2013
CSII
29.16Orbital atherectomy systemCalcified coronary arteriesPMAPMA approved Oct 22 201310/23/2013
ALIOF
106.96Macitentan (Opsumit)Pulmonary arterial hypertensionApprovedApproved Oct 18 201310/22/2013
ATRS
2.35OTREXUPRheumatoid arthritis (RA)ApprovedApproved Oct 14 201310/16/2013
CNDO
2.37TSO - (CNDO-201) (TRUST-I)Crohn’s diseasePhase 2Phase 2 endpoint not met Oct 201310/15/2013
ARIA
6.10Iclusig (ponatinib) Advanced Medullary Thyroid CancerPhase 2Partial hold lifted. Ongoing10/11/2013
MDCO
28.40Angiomax (bivalirudin) Peripheral endovascular intervention (PEI)Phase 3Phase 3 enrolment commenced Oct 201310/11/2013
CTIC
2.19PacritinibMyelofibrosisPhase 3Second Phase 3 trial (PERSIST-2) is planned to initiate in 4Q 2013. 10/08/2013
CRIS
1.67Erivedge (vismodegib)Cancer - relapsed/ refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS)Phase 1b/2Phase 1b/2 initiated Oct 201310/06/2013
LGND
54.67Bazedoxifene/Conjugated Estrogens (BZA/CE), formerly known as APRELAMenopausal symptomsApprovedApproved Oct 3 201310/06/2013
INFI
15.29Retaspimycin Hydrochloride with everolimusCancer - NSCLCPhase 2Phase 2 enrolment completed. Does not plan to further development09/27/2013
CNAT
5.34EmricasanSevere alcoholic hepatitisPhase 2Phase 2 initiated Sept 201309/22/2013
ONTX
3.53RigosertibCancer - relapsed or metastatic head and neck cancersPhase 2Initiated mid-201309/22/2013
XLRN
39.24Sotatercept Multiple myelomaPhase 2Phase 2 ongoing09/22/2013
XLRN
39.24Sotatercept Diamond-Blackfan anemia Phase 2Phase 2 ongoing09/22/2013
XLRN
39.24SotaterceptMyelofibrosisPhase 2Phase 2 ongoing09/22/2013
PBMD
0.80CVacCancer - ovarianPhase 3Phase 3 initiated Jan 2012. Enrolment halted Sept 201309/19/2013
NKTR
14.62Etirinotecan pegol NKTR-102Cancer - ovarianPhase 2Completed Dec 2012. Considering future development09/18/2013
NVAX
7.37Seasonal Influenza VaccineSeasonal FluPhase 2Further Phase 2 trials planned09/18/2013
OPXA
0.83Tovaxin (Tcelna)Relapsing Remitting MS (RRMS)Phase 2bFurther development pending funding09/18/2013
PSTI
2.68PLX-PAD (stem cells)Intermittent claudication, or ICPhase 2Phase 2 put on clinical hold Jun 2013. Lifted Sept 201309/17/2013
CNDO
2.37TSO - (CNDO-201)Ulcerative colitisPhase 2Phase 2 initiated Sep 201309/15/2013
DCTH
1.23CHEMOSAT systemCancer - unresectable metastatic ocular melanoma in the liverCRLCRL Sept 13 201309/15/2013
ISIS
71.28OGX-427 in combination with gemcitabine and cisplatin Borealis-1Cancer - bladderPhase 2Phase 2 data due 2H 201409/12/2013
OPK
10.84Fermagate Tabletshyperphosphatemia in CKD patients on chronic hemodialysisPhase 3Phase 3 data due 1H 201709/12/2013
OPK
10.84hGH-CTPAdults - growth hormone deficiencyPhase 3Initiated Phase 3 Jun 2013. 09/12/2013
IMMU
4.73Veltuzumab intravenousCancer - NHL Non-Hodgkin lymphomaPhase 2Phase 3 planned, need funding09/10/2013
ONCY
0.47Intravenous REOLYSIN with paclitaxel & carboplatinCancer - squamous cell carcinoma of the lung (SCCLC)Phase 2Final data released Sept 201309/10/2013
BIOD
1.46BIOD-123Diabetes - Type 1Phase 2Phase 2 data released Sept 201309/09/2013
CYTR
2.77BafetinibCancer - B-Cell Chronic Lymphocytic Leukemia (B-CLL)Phase 2Phase 2 proof of concept completed. Seeking partner for further development09/08/2013
CYTR
2.77BafetinibCancer - B-cell chronic lymphocytic leukemia (B-CLL)Phase 2Phase 2 proof of concept completed. Seeking partner for further development09/08/2013
DARA
0.81KRN5500Pain - Neuropathic Phase 2Seeking partner for development09/08/2013
ENDP
78.87AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadismApprovedApproved March 6 201409/06/2013
TTHI
6.83ELND005-DS201Down syndromePhase 2Phase 2 initiated Sept 201309/05/2013
ESPR
46.31ETC-1002-007HypercholesterolemiaPhase 2aTop-line data released Sept 03 201309/04/2013
CYTK
7.38Omecamtiv mecarbil ATOMIC-AHFAcute heart failurePhase 2bData released Sept 3 at EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS missed primary endpoint09/03/2013
BCRX
10.99UlodesineGoutPhase 2bPhase 3 initiation pending partnership09/02/2013
BCRX
10.99UlodesineModerate renal impairmentPhase 2Phase 3 initiation pending partnership09/02/2013
ACOR
43.76AC105Acute treatment of spinal cord injuryPhase 2Phase 2 trial initiated Sept 201309/01/2013
AEZS
0.52AEZS-108Metastatic Hormone-Resistant Prostate CancerPhase 2Ongoing09/01/2013
AGEN
4.96G-200Cancer - Glioblastoma (GBM) 2nd linePhase 2Enrolling 1H 201309/01/2013
PCYC
158.55IMBRUVICA Cancer - relapsed or refractory MCL mantle cell lymphomaApprovedApproved Nov 13 201308/31/2013
ACUR
0.55Study AP-ADF-301 (Study 301)Abuse LiabilityPhase 2Disappointing data released Aug 201308/28/2013
SUPN
8.57Trokendi XR SPN-538EpilepsyApprovedApproved Aug 19 201308/22/2013
NSPR
0.75MGuardSTEMI - ST segment elevation myocardial infarctionInvestigational Device Exemption (IDE) support trialMaster 12-month data due 4Q 201308/18/2013
NSPR
0.75MGuardSTEMI - ST segment elevation myocardial infarctionInvestigational Device Exemption (IDE) support trialMaster 2 enrolment due to be completed 3Q 2014. Data due 4Q 201508/18/2013
SGEN
32.30ADCETRIS + Rituxan and standard chemotherapy (R-CHOP) Diffuse large B-cell lymphoma Phase 2Phase 2 initiated August 201308/16/2013
CMRX
38.26CMX001AdV diseasePhase 2Phase 2 top line data released Aug 201308/15/2013
IMMY
6.98Impracor Topical NSAIDPain - anti-inflammatory creamPhase 3Phase 3 initiation delayed08/14/2013
OSIR
16.89GrafixDiabetic Foot UlcersData released Aug 201308/14/2013
RPTP
9.29DR CysteamineCystinosisApprovedApproved08/09/2013
ARRY
7.11AMG 151 (ARRY-403) Glucokinase activatorType 2 diabetesPhase 2AMG returned rights to ARRY08/07/2013
ARRY
7.11ARRY 380Cancer - metastatic breast cancerPhase 3Phase 3 planned with ONCY08/07/2013
NBY
0.60Auriclosene (NVC-422)Urine infectionPhase 2Phase 2 Topline Data released 3Q08/06/2013
ANIK
39.60CingalOsteoarthritisPhase 3Phase 3 initiated 2Q 201308/01/2013
OGXI
2.09OGX-427 and carboplatin and pemetrexed - SpruceTrialNon-squamous, non-small cell lung cancer (NSCLC)Phase 2Phase 2 enrolment commenced Jul 201308/01/2013
PCYC
158.55IMBRUVICA - SPARK (MCL2001)R/R MCL who progress after bortezomib therapyPhase 2Enrolment completed08/01/2013
TSRO
40.80TSR-011Cancer - NSCLCPhase 1/2Phase 2 dosing to be finalised by end of 201307/26/2013
CBST
101.94Bevenopran (CB-5945) ASCENTChronic opioid-induced constipation (OIC).Phase 3Three Phase 3 efficacy trials initiated Jul 201307/21/2013
MNOV
3.54MN-166Progressive multiple sclerosis (progressive MS).Phase 2bPh2b initiated Jul 2013. Data due 201607/21/2013
ARRY
7.11MEK162 (ARRY-162) - MILORecurrent low-grade serous ovarian cancer (LGSOC)Phase 3Phase 3 initiated July 201307/03/2013
INSM
14.89ARIKAYCEcystic fibrosisPhase 3 Phase 3 Euro data released 1 July 2013. Met endpoint but slighly inferior data to competition07/02/2013
PSDV
4.09Injectable sustained-release micro-insertPosterior uveitisPhase 3Pivotal trial initiated Jul 2013 (first of two Phase 3 trials)07/02/2013
PPHM
1.33Bavituximab plus carboplatin and paclitaxelCancer - front-line NSCLCPhase 2PFS disappointing data released Mar 2013. OS data showed not statistical meaningful improvement. Will not pursue Phase 306/28/2013
PBMD
0.80CVacCancer - resectable pancreatic cancer, metastatic colorectal cancer, and triple-negative breast cancerPhase 2Phase 2 trials planned06/25/2013
THRX
11.78VIBATIV (telavancin hydrochloride) for injectionHospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)ApprovedApproved Jun 21 201306/24/2013
EPZM
20.10EPZ-6438Non-Hodgkin lymphoma - EZH2 point mutationPhase 1/2Initiated Phase 1/2 Jun 201306/14/2013
CERS
5.29INTERCEPT Acute and Chronic AnemiaPhase 3Phase 3 Eruopean trials initiated 201306/12/2013
FLML
14.48Bloxiverz (neostigmine methylsulfate)Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgeryApprovedApproved Jun 306/05/2013
TGTX
14.08Ublituximab TG-1101Relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) Phase 1/2Phase 1/2 trial initiated Sep 2012. Data at ASH Dec 2013 and at ASCO 201306/05/2013
CTIC
2.19BrostallicinCancer - breastPhase 2Interim data released Dec 2012. Final data released ASCO 201306/03/2013
DEPO
18.72SEFELSAHot flashesCRLCRL May 31 201306/01/2013
EPZM
20.10EPZ-5676Mixed lineage leukemia, or MLL-rPhase 1Phase 1 initiated Sep 201205/31/2013
VRX
159.66EfinaconazoleOnychomycosisPDUFACRL May 28 201305/29/2013
SGEN
32.30ADCETRISCancer - CD30-positive Nonlymphomatous MalignanciesPhase 2Enrolling05/25/2013
ONCY
0.47Intravenous REOLYSIN in combination with paclitaxel and carboplatinCancer - metastatic melanomaPhase 2Prelim data released May 201305/23/2013
ONTY
1.53PX-866Cancer - glioblastomaPhase 2Phase 2 data due at ASCO05/18/2013
LGND
54.67Captisol-enabled DelafloxacinAcute bacterial skin and skin structure infections (ABSSSI)Phase 3Phase 3 initiated by Rib-X Pharmaceuticals May 201305/15/2013
SPPI
6.77ZevalinDiffuse Large B-Cell Lymphoma (DLBCL)Phase 3Phase 3 initiated Sep 201205/13/2013
LXRX
0.92LX1032 Telotristat etiprateUlcerative colitisPhase 2Ongoing05/11/2013
SLXP
125.92EIR rifaximin Crohn’s diseasePhase 3Phase 3 due to be initiated 2H 201305/11/2013
THRX
11.78BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)ApprovedApproved May 10 201305/11/2013
SNSS
2.20VoreloxinCancer - newly diagnosed elderly acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Phase 2/3First two planned interim assessments of the LI-1 trial due 201305/10/2013
SPPI
6.77ApaziquoneCancer - BladderPhase 3Failed to meet primary endpoint in Phase 3 trial - Apr 2012. NDA possible 201405/10/2013
CYTR
2.77TamibaroteneCancer - non-small-cell lung cancer (NSCLC)Phase 2bTerminated May 201305/09/2013
SGEN
32.30ADCETRIS in combination with bendamustineCancer - second-line HLPhase 1/2Phase 1/2 initiated Jun 201305/08/2013
ISIS
71.28TG-1101Cancer - hepatocellular carcinoma (HCC)Phase 1/2Phase 2 initiated May 201305/07/2013
XOMA
3.48XOMA 052 gevokizumabType 1 DiabetesPhase 205/04/2013
CCXI
8.49CCX354 (GSK2941266) - (CARAT-2)Rheumatoid arthritis.Phase 2Completed05/03/2013
CCXI
8.49Vercirnon CCX282 - (SHIELD-2)Crohn's diseasePhase 3Initiated in Nov 2011.05/03/2013
INCY
79.90INCB18424 ruxolitinibCancer- Children with hematologic malignancies and solid tumorsPhase 1/2Ongoing05/03/2013
INCY
79.90RuxolitinibPSTAT3+ Breast CancerPhase 2Initiated Phase 2 2Q 2012. Ongoing05/03/2013
INCY
79.90RuxolitinibEstrogen Receptor Positive Breast CancerPhase 2Initiated Phase 2 2Q 2012. Ongoing05/03/2013
PCYC
158.55IMBRUVICACancer - relapsed or refractory follicular lymphomaPhase 2Phase 2 ongoing05/02/2013
PCYC
158.55IMBRUVICA Cancer - newly diagnosed CD20 positive non-Hodgkin's lymphomaPhase 1b/2Update at ASCO 201305/02/2013
MNTA
10.63Generic CopaxoneMultiple sclerosisaNDAFiled 2007. FDA still reviewing05/01/2013
OGXI
2.09OGX-427 Borealis-2Cancer - advanced or metastatic bladder cancerPhase 2Phase 2 initiated Apr 201305/01/2013
SNTA
2.47Ganetespib CHIARA trial Cancer - ALK+ NSCLC patientsPhase 205/01/2013
INCY
79.90INC280 (formerly INCB28060)Advanced hepatocellular carcinomaPhase 2Phase 2 initiated Apr 201304/30/2013
PTN
0.70PL-3994Acute exacerbations of asthmaPhase 2aCompleted04/28/2013
QLTI
4.41punctal plug drug deliveryGlaucomaPhase 2Sold to Mati04/28/2013
ASMB
8.54VEN 308 (phenylephrin)Ileal pouch anal anastomosis, or IPAAPhase 2bPhase 2b initiation dependent on funding04/27/2013
LGND
54.67Merck Captisol ProgramUndisclosedPhase 3Expect Merck to potentially file a 505(b)(2) in 201304/27/2013
LGND
54.67Captisol-enabled Clopidogrel - MDCO-157Phase 3Phase 3 planned by MDCO04/27/2013
LGND
54.67DinaciclibRefractory chronic lymphocytic leukemia (CLL)Phase 2b/3Phase 2b/3 trial initiated Oct 201204/27/2013
LGND
54.67MEDI-528Asthma Phase 2Ongoing04/27/2013
LGND
54.67PromactaOncology-related thrombocytopenia in patients with solid tumors, Myelodysplastic Syndrome (MDS), or Secondary Acute Myeloid Leukemia (AML) after MDSPhase 2Ongoing04/27/2013
LGND
54.67MK-8931Mild-to-moderate Alzheimer's diseasePhase 2/3Phase 2/3 initiated by Merck in Dec 201204/27/2013
LGND
54.67Captisol-enabled Carbamazepine-IVAcute seizure disorderPhase 3Phase 3 ongoing04/27/2013
LGND
54.67LGD-4033Muscle wasting associated with cancer (cachexia), acute rehabilitation (e.g. hip fracture), and acute illness.Phase 2Phase 2 pending04/27/2013
LXRX
0.92LX2931RA + autoimmune diseasesPhase 2Phase 2 Data did not achieve statistical significance 201004/27/2013
MACK
9.59MM-398Cancer - ColorectalPhase 2Ongoing04/27/2013
MNOV
3.54MN-166Chronic medication overuse headache (MOH) painPhase 2Phase 2 to be completed mid 201304/27/2013
NKTR
14.62Etirinotecan pegol NKTR-102Cancer - colorectalPhase 2Enroling04/27/2013
NKTR
14.62Cipro DPI (Cipro Dry Powder Inhaler)Non-cystic fibrosis bronchiectasisPhase 3In Aug 2012, Bayer initiated a global Phase 3 program called RESPIRE. Data due mid-2015 as per JPM conference slides 2014.04/27/2013
NVGN
2.34Intravenous ME-143Cancer - triple-negative breast cancerPhase 2Phase 2 enrolling04/27/2013
OMER
22.86OMS201UrologyPhase 2Phase 2 planning. Company have no plans for 2013, but will resume when they have adequate resources 04/27/2013
ONCY
0.47Intravenous Administration of REOLYSIN in combination with paclitaxel and carboplatinNon-small cell lung with K-RAS or EGFR-activated tumoursPhase 2Ongoing04/27/2013
ONCY
0.47REOLYSIN with paclitaxel Cancer - ovarian, fallopian tube or primary peritonealPhase 2Ongoing04/27/2013
OPK
10.84Factor VIIa-CTPHemophiliaPhase 2Intend to initiate Phase 2 in 201404/27/2013
OREX
5.41EmpaticEpilepsyPhase 2bPhase 3 planned. Needs partner04/27/2013
OSIR
16.89ProchymalCrohn’s diseasePhase 3Enrollment re-started May '10.Ongoing04/27/2013
OSIR
16.89ProchymalAcute myocardial infarctionPhase 2Interim data released Jul 2012. Trial extended for further four years04/27/2013
PGNX
6.14Oral RelistorChronic, Non-Cancer Pain Subjects with Opioid-Induced ConstipationPhase 3Phase 3 completed. Further progress on hold04/27/2013
PPHM
1.33BavituximabCancer - LiverPhase 2Phase 2 part of trial is enrolling04/27/2013
PSTI
2.68PLX-PAD (stem cells)Pulmonary Arterial Hypertension (PAH) Phase 1Phase 1 planned04/27/2013
RNN
0.71ZoraxelErectile DysfunctionPhase 2aPhase 2a complete. Phase 2b development requires partner04/27/2013
RNN
0.71ArchexinCancer - pancreaticPhase 2aPhase 2 completed 201204/27/2013
RPRX
8.61ProellexEndometriosisPhase 2Phase 2 to resume while on partial clinical hold. Low dose only. Enrollment due to be completed 2Q 2013. Complete 4Q 201304/27/2013
RPTP
9.29ConviviaALDH2Phase 2aPhase 2 completed, seeking partner04/27/2013
SCMP
15.18Amitiza/ LubiprostoneChronic idiopathic constipationApprovedApproved 200604/27/2013
SGEN
32.30ADCETRISCancer - CD30-positive non-Hodgkin lymphomaPhase 2Initiated Aug 2011. Interim data released at ASH 201204/27/2013
SGEN
32.30SGN-75Cancer - advanced metastatic renal cell carcinoma (RCC)Phase 1bPhase 1b initiated Aug 2012. Ongoing04/27/2013
SNTA
2.47ElesclomolCancer - ovarianPhase 2Ongoing04/27/2013
SNTA
2.47STA-9090 GanetespibCancer - rectalPhase 2Phase 2 ongoing04/27/2013
SNTA
2.47STA-9090 GanetespibCancer - hepaticPhase 1/2Ongoing04/27/2013
SPPI
6.77BelinostatCancer - Carcinoma of Unknown Primary (CUP)Phase 2Primary endpoint of PFS was not met although there was a highly significant increase in the response rate 04/27/2013
SPPI
6.77SPI-1620Cancer - recurrent or progressive carcinomaPhase 2Phase 2 to be initiated 2H 201304/27/2013
STEM
1.05HuCNS-SC cellsPelizaeus-Merzbacher disease (PMD)Phase 1/2Phase 1 completed04/27/2013
STML
13.21SL-701Cancer - blastic plasmacytoid dendritic cell neoplasm (BPDCN)Phase 2b pivotalPhase 2b planned04/27/2013
STML
13.21SL-701Cancer- adult relapsed or refractory acute myeloid leukemia (AML) Phase 2bPhase 2b planned04/27/2013
STML
13.21SL-701Cancer - malignant gliomaPhase 2bPhase 2b planned04/27/2013
STML
13.21SL-701Cancer - second line glioblastoma (GBM)Phase 2bPhase 2b planned04/27/2013
SYN
1.53FlupirtineFibromyalgiaPhase 2Pending. Partner Meda has received the go-ahead from the FDA to conduct a Phase 2 proof of concept trial04/27/2013
THRX
11.78TD−1211Opioid-induced constipation (OIC)Phase 2bPhase 2b data released Jul 2012. Evaluating Phase 3 strategy due to FDA requirements for this class of drug04/27/2013
VRX
159.66LuliconazoleTinea cruris, pedis and corporisPDUFAPDUFA date Dec 11 201304/27/2013
XNPT
8.60XP21279Parkinson's DiseasePhase 2bData released Dec 2011, no statistical improvement over Sinemet. However Phase 3 planned dependent on funding04/27/2013
XOMA
3.48XOMA 052 GevokizumabNeutrophilic Dermatoses and Schnitzler syndromePhase 3Phase 3 planned in one or more of Neutrophilic Dermatoses and Schnitzler syndrome. Will meet with FDA in 201304/27/2013
XOMA
3.48XOMA 052 GevokizumabModerate to Severe Acne VulgarisPhase 2Initiated Phase 2 Dec 2011. Topline Data released Jan 2013. Phase 3 planned04/27/2013
CASI
1.68MKC-1Cancer - NSCLCPhase 2Need funding to continue04/26/2013
CASI
1.68MKC-1Cancer - PancreaticPhase 2Need funding to continue04/26/2013
CYCC
0.61SapacitabineCancer - NSCLCPhase 2Ongoing04/26/2013
CYTR
2.77INNO-206 aldoxorubicinCancer Phase 2Phase 2 clinical trial with INNO-206 for pancreatic cancer initiated Apr 2012. No objective responses to date04/26/2013
CYTR
2.77TamibaroteneCancer - Acute promyelocytic leukemia Phase 2Phase 2 SPA obtained but not currently open04/26/2013
DSCO
1.31Surfaxin LS - lyophilized dosage form of SURFAXINNeonatal RDSPhase 2 Talks with FDA regarding further development 04/26/2013
IMMU
4.73EpratuzumabCancer - ALLPhase 2Phase 2 initial data presented at ASH 201204/26/2013
IMMU
4.73Epratuzumab in combination with chemotherapy in pediatric patients Cancer - ALLPhase 3Phase 3 planned04/26/2013
ANAC
34.15AN2728Mild-to-moderate plaque-type psoriasisPhase 2bPromising Prelim Phase 2b data released Jun 2011. Phase 3 planning on hold04/25/2013
APRI
1.22VitarosErectile DysfunctionApproved in Canada. Partner "Warner Chilcott continues to pursue the approval of the drug"04/25/2013
ARQL
1.10Tivantinib (ARQ 197)Cancer - Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 2Phase 2 initiated Jul 2012. Data due 201304/25/2013
ARRY
7.11ARRY 614MDSPhase 1Phase 3 decision to be made late 201304/25/2013
ARRY
7.11DanoprevirHCV Hepatitis C Phase 2Phase 3 decision to be made 201304/25/2013
ARRY
7.11ARRY 543/ ASLAN001 Cancer - HER2/EGFR inhibitor for gastric cancerPhase 2Ongoing04/25/2013
CPIX
5.97Hepatoren HRSPhase 2Ongoing04/25/2013
CTIC
2.19PixantroneCancer - Relapsed/refractory diffuse large B-cell lymphoma ("DLBCL")PivotalInitiated Mar 2011. Ongoing04/25/2013
CTIC
2.19PixantroneCancer - Non-Hodgkin lymphomaCRLNDA withdrawn Jan 2012. Not planning to resubmit NDA as of early 2013, but may evaluate a possible resubmission strategy based on the data generated from the ongoing PIX306 clinical trial04/25/2013
ACAD
31.88AGN201781Chronic painPhase 2Phase 2 completed. Futher development pending funding04/24/2013
ACHN
15.99ACH-3102 in combination with ribavirinGenotype 1b, IL28B CC genotype, HCVPhase 2Phase 2 initiated Oct 2012. Interim SVR4 results following 12 weeks released Apr 201304/24/2013
AEZS
0.52AEZS-108Cancer - OvarianPhase 2Complete04/24/2013
AEZS
0.52AEZS-130Cancer cachexiaPhase 2Phase 2 first patient recruited Aug 2012. Ongoing04/24/2013
AGEN
4.96HerpVGenital herpesPhase 2Phase 2 enrolment completed Feb 201304/24/2013
ALKS
69.81Paliperidone Palmitate 3 Month FormulationSchizophreniaPhase 3Phase 3 initiated Jun 2012. Expect to be completed 2H 201404/24/2013
ENTA
44.92Aviator - ABT-450/r in various combinationsHCV genotype 1 non-cirrhotic patientsPhase 2bPhase 2b data released Apr 201304/24/2013
SCMP
15.18Amitiza/ LubiprostoneOpioid-induced bowel dysfunctionApprovedApproved Apr 23 201304/24/2013
BLRX
1.83BL-7040 Inflammatory Bowel DiseasePhase 2aPhase 2a data released Apr 201304/19/2013
NVAX
7.37RSV vaccineRespiratory Syncytial Virus (RSV)Phase 2Initiated Phase 2 trials Sept 2012. Topline data released Apr 201304/03/2013
UTHR
145.30314dAdd-on therapy to TyvasoPhase 3Phase 3 planned04/01/2013
UTHR
145.30Ch14.18 AntibodyCancer - neuroblastomaPhase 3Phase 3 completed. Human pharmacokinetics study ongoing. BLA filing planned04/01/2013
ENDP
78.87ODM-201 (ARAFOR)Castrate resistant prostate cancerPhase 2Ongoing03/31/2013
ENDP
78.87 EN3342SchizophreniaPhase 1/2Ongoing03/31/2013
LMNX
18.28MK-8931Alzheimer’s DiseasePhase 2/3Phase 1/2 ongoing by MRK03/31/2013
CNDO
2.37CNDO-109 Cancer - acute myeloid leukemia (AML)Phase 1/2Phase 1/2 initiated Nov 201203/29/2013
EBS
28.39BioThrax Anthrax - pre-exposure prophylaxis indicationApprovedApproved May 17 201203/29/2013
EBS
28.39MVA85A Preventing tuberculosis (TB) in infantsPhase 2bPhase 2b complete03/29/2013
EBS
28.39TRU-016 in combination with bendamustine Study 16201Cancer - Refractory Chronic Lymphocytic Leukemia (CLL)Phase 2Phase 2 data due 2H 201303/29/2013
PRGO
157.00Betamethasone Valerate Foam 0.12%Generic equivalent of Luxiq FoamApprovedApproved Nov 201203/29/2013
NAVB
1.72NAV4694Cerebral Beta-Amyloid When Compared With Postmortem HistopathologyPhase 3Phase 3 enrloment commenced Jun 201303/28/2013
CASI
1.68ENMD-2076Cancer - OvarianPhase 2Ongoing. Enrolment closed03/22/2013
ENTA
44.92Co-Pilot -ABT-450/r plus ABT-333 plus weight-based ribavirinHCV genotype 1, non-cirrhotic patientsPhase 2Ongoing03/22/2013
ENTA
44.92Navigator - ABT-450/r with Abbott’s NS5A inhibitor ABT-267 with and without ribavirinHCV Phase 2Ongoing03/22/2013
ICPT
165.76Obeticholic acid (OCA)Adult nonalcoholic steatohepatitis (NASH) patients. Phase 2Phase 2 Japan trial initiated Jan 2013. Complete 1H 201603/19/2013
OMER
22.86OMS103HPPostoperative joint function Phase 3Data released Dec 2012. Missed primary endpoint. 03/19/2013
NAVB
1.72LymphoseekLymphatic-tissue tracing agentApprovedApproved Mar 13 201303/14/2013
ALIOF
106.96PonesimodModerate to severe chronic plaque psoriasis.Phase 3Phase 3 planned03/10/2013
ALIOF
106.96CadazolidClostridium difficile associated diarrhea (CDAD)Phase 3Phase 3 planned03/10/2013
ZIOP
7.24PalifosfamideCancer - recurrent metastatic germ cell (testicular and ovarian) tumorsPhase 2Phase 2 initiated Mar 201303/07/2013
AEZS
0.52AEZS-108Cancer - Refractory triple-negative breast cancerPhase 2First patient enrolled Feb 201302/24/2013
IMGN
6.33Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - KadcylaCancer - 2nd-line HER2+ MBCApprovedApproved Feb 22 201302/24/2013
ISIS
71.28ISIS-TTRRxFamilial amyloid polyneuropathyPhase 2/3Phase 2/3 trial initiated early 201202/20/2013
PPHM
1.33Bavituximab with gemcitabineCancer - pancreatic Phase 2Patient enrolment completed Jun 2012. Interim data released Feb 2013. Evaluating next steps02/14/2013
CYTK
7.38Oral formulations of omecamtiv mecarbil COSMIC-HFHeart failure and left ventricular systolic dysfunction.Phase 2Phase 2 enrolment commenced Feb 201302/13/2013
ACHN
15.99007 Trial of Sovaprevir and ACH-3102 and ribavirinPhase 2Phase 2 rapid virologic response, or RVR, of Sovaprevir and ACH-3102 combo in HCV Hepatitis C patients released Sept 201302/10/2013
LXRX
LX4211Patients with type 2 diabetes and moderate to severe renal impairmentPhase 2Phase 2 data released Sept 2013. Met endpoint02/10/2013
VICL
CollategenePeripheral arterial diseasePhase 2SPA for Phase 3 obtained. Phase 3 planning02/07/2013
CYTK
tirasemtiv (formerly CK-2017357)Myasthenia gravis Phase 2aData released Nov 201202/06/2013
NKTR
Etirinotecan pegol NKTR-102Cancer - NSCLCPhase 2Phase 2 initiated Feb 201302/06/2013
ARRY
ARRY 797Osteoarthritis of the KneePhase 2Seeking partner for further development02/05/2013
HEB
Ampligen CFSCRLCRL Feb 4 2012. Resubmission. More trials required. Intends to appeal02/05/2013
HPTX
RavictiUrea cycle disorders.ApprovedApproved Feb 1 201302/02/2013
MDGN
INFRADUREHepatitis C HCVPhase 1/2Two Phase I/II trials in Israel commenced enrolment Jan 201301/31/2013
ISIS
Mipomersen (KYNAMRO)Homozygous familial hypercholesterolemia (HoFH)ApprovedApproved Jan 29 201301/30/2013
CBST
Surotomycin (CB-315)C. difficile-associated diarrhea (CDAD).Phase 3Phase 3 initiated Jul 2012. NDA filing 201501/25/2013
CBST
Ceftolozane/ tazobactam CXA-201Ventilator-associated bacterial pneumonia (VABP) for ceftolozane/tazobactamPhase 3Phase 3 trial to be initiated around mid-year 2013.01/25/2013
SGEN
ADCETRIS ECHELON-2Cancer - front-line mature T-cell lymphomas, including sALCLPhase 3Phase 3 initiated Jan 201301/25/2013
INO
(INO-8000)Hepatitis C Phase 1/2Ongoing01/10/2013
AEGR
LomitapideHomozygous familial hypercholesterolemia (HoFH)ApprovedApproved Dec 24 201212/25/2012
ALXA
Staccato loxapine (ADASUVE)SchizophreniaApprovedApproved Dec 21 201212/23/2012
NPSP
GATTEXShort Bowel Syndrome ApprovedApproved Dec 21 201212/23/2012
OGXI
OGX-427 in combination with Zytiga - Pacific TrialCancer - castrate-resistant prostatePhase 2Initiated Phase 2 late Dec 201212/20/2012
SOMX
SilenorInsomniaApprovedTo be acquired by PTX12/14/2012
INO
DNA vaccineLeukemia Phase 2Interim Phase 2 data released Dec 201212/12/2012
PPHM
CotaraCancer - GlioblastomaPhase 2Phase 3 planning. Needs partner to advance12/10/2012
EXEL
XL184 cabozantinibCancer - Medullary thyroid ApprovedApproved Nov 29 201211/30/2012
TTHI
ELND005Alzheimer'sPhase 2Phase 2 enrolment commenced Nov 201211/28/2012
XOMA
Perindopril and Amlodipine (PATH)CardiovascularPhase 3Phase 3 trial met endpoint. NDA planned11/21/2012
LGND
Promacta/RevoladeThrombocytopenia (low blood platelet counts) in patients with chronic hepatitis CApprovedsNDA approved Nov 19 201211/20/2012
DEPO
DM-1992Parkinson's diseasePhase 2Phase 2 data released Nov 2012. Considering partnership opportunites to advance product.11/08/2012
SGEN
ADCETRIS ECHELON-1Cancer - front-line advanced stage Hodgkin lymphomaPhase 3Phase 3 initiated Nov 201211/03/2012
SUPN
Oxtellar XR SPN-804Adjunctive therapy for epilepsyApprovedApproved Oct 22 201210/24/2012
PGNX
MIP-1404Cancer - prostate cancerPhase 2Phase 2 initiated Oct 201210/21/2012
MDVN
XTANDICancer - prostate 2nd lineApprovedApproved Aug 31 201209/02/2012
IRWD
Linaclotideirritable bowel syndrome with constipation (IBS‐C).ApprovedApproved Aug 30 201208/31/2012
RVX
RVX-208 (SUSTAIN trial)Coronary placque removalPhase 2bData released Aug 2012. Endpoints met08/29/2012
SPPI
OzarelixCancer - prostatePhase 2bPhase 2b initiated Aug 201208/16/2012
ASMB
VEN 309 (iferanserin)Symptomatic hemorrhoidsPhase 3First of two Phase 3 trials initiated Aug 2011. Did not meet endpoint08/12/2012
CCXI
CCX140Type 2 Diabetes and AlbuminuriaPhase 2Phase 2 completed07/28/2012
CCXI
CCX354 (GSK2941266) -(CARAT-1)Rheumatoid arthritis.Phase 2Completed07/28/2012
AMRN
Vascepa Elevated triglyceride levelsApprovedApproved Jul 26 201207/27/2012
HZNP
16.21LODOTRA (RAYOS)Rheumetoid ArthritisApprovedApproved 7/26/201207/27/2012
LGND
Kyprolis (Carfilzomib)Cancer - multiple myelomaApprovedApproved Jul 2012. Partnered with ONXX07/21/2012
CORT
Corlux - KorlymCushing's SyndromeApprovedApproved Feb 17 201207/20/2012
VVUS
QnexaObesityApprovedApproved Jul 18 201207/18/2012
OSUR
OraQuickHIV testApprovedApproved Jul 3 201207/03/2012
SPPI
LucanthonePrimary therapy for Glioblastoma Multiforme (GBM)Phase 2Phase 2 initiated Jul 201207/03/2012
ARNA
LorcaserinObesityApprovedApproved Jun 27 201206/28/2012
RGEN
RG1068 - SecreFloPancreatic imagingCRLCRL issued Jun 22 201206/22/2012
XNPT
HorizantPostherpetic NeuralgiaApprovedApproved Jun 6 201206/07/2012
ONCY
REOLYSIN with FOLFOX-6 plus bevacizumabCancer - advanced or metastatic colorectal cancerPhase 2Phase 2 planned05/04/2012
PLX
TaliglueraseGaucher diseaseApprovedApproved May 1 201205/02/2012
APRI
PrevOncoCancer - HCC - liver cancerPhase 2Phase 3 and SPA in discussions with the FDA04/06/2012
KERX
PerifosineCancer - ColorectalPhase 3Primary endpoint not met Apr 201204/03/2012
DSCO
Surfaxin Respiratory Distress Syndrome - SevereApprovedApproved Mar 6 201203/07/2012
CBRX
PROCHIEVE (progesterone gel)Reduction of risk of preterm birthCRLCRL Feb 26 201202/28/2012
VNDA
Fanapt (Injectable) SchizophreniaApprovedApproved02/15/2012
CRIS
GDC-0449 vismodegib (everolimus)Cancer - Advanced Basal Cell CarcinomaApprovedApproved Jan 31 201201/30/2012
ATRS
AnturolOveractive bladderApprovedApproved Dec 8 201112/08/2011
SPPI
FusilevCancer - Removal of BioscanApprovedApproved Nov 20, 201111/21/2011
INCY
INCB18424 ruxolitinibMyelofibrosisApprovedApproved Nov 201111/20/2011
CPIX
AcetadoteNon-Acetaminophen Induced Acute Liver FailureCRLCRL received Dec 2010. 11/05/2011
MELA
MelafindCancer - melanoma detectionApprovedApproved Nov 201111/05/2011
PCRX
EXPARELPostsurgical painApprovedFDA Approved Oct 201110/31/2011
SQNM
SensiGene T21 Laboratory Developed Test (LDT) - MaterniT21Prenatal test for Down SyndromeR&DLaunched Oct 201110/17/2011
SGEN
ADCETRISCancer - Anaplastic large cell lymphomaApprovedAPPROVED Aug 19 201108/20/2011
SGEN
ADCETRISCancer - Relapsed & Refractory Hodgkin lymphomaApprovedAPPROVED Aug 19 201108/20/2011
ACUR
OXECTAPain reliefApprovedApproved Jun 17, 201106/20/2011
CYTK
tirasemtiv (formerly CK-2017357)Peripheral artery diseasePhase 2aData Ph2a released Jun 201106/03/2011
SPPI
FusilevCancer - ColorectalApprovedApproved Apr 29 201105/01/2011
XNPT
HorizantRestless LegsApprovedFDA Approved Apr 6 201104/07/2011
DEPO
DM-1796Postherpetic neuralgia - shinglesApprovedApproved Jan 28 201101/30/2011
CPIX
AcetadoteAcute liver failureApprovedApproved Jan 13, 201101/14/2011
EBS
NuThrax - AV7909Anthrax Phase 2
FOLD
AT2220/ERT enzyme replacement therapy (010)Pompe DiseasePhase 2
ORPN
CabalettaMachado Joseph diseasePhase 2Phase 2 ongoing
ORPN
CabalettaKennedy’s diseasePhase 2Phase 2 planned for 2015
THLD
TH-302 Cancer - Advanced MelanomaPhase 2Phase 2 initiated Aug 2013.

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.

16 Responses to “Company Pipeline Database”

  1. Shamil says:

    Check dates for RIGL, they entered in a reverse order (07/03/2012, instead of 03/07/2012).

    • admin says:

      Thanks for that! I live in New Zealand so am used to having the date like 28/03/12 so unfortunately I’m always prone to making that error. Error has been fixed. Thanks!

  2. Shamil says:

    Tickers are gone! And could you sort the list update desc (newest at the top) by default?

    • admin says:

      I’m not sure what has happened with the system but will contact my webmaster and provide an update as soon as possible. Apologies for the inconvenience.

    • admin says:

      In response to the question about sorting the database by date, I think I will keep it as it is as it’s much easier for me to maintain it at my end. Also, you can just click the “updated” tab an it’ll sort it that way for you.

  3. Mark says:

    Site is great. Any reason the Phase III’s of the BMS’s and Pfizer’s of the world are left off?

    • admin says:

      Hi Mark,

      When I first started the FDA Calendar and Clinical Database about three years ago, I made the decision to focus on small-mid cap NASDAQ/AMEX listed companies, mainly due to reader demand and the sheer workload involved in having to follow large-cap companies as well.

      However, I made a decision this year that I will now add large cap companies to the database. I started with ACOR early this week and will continue to add a few each week. I’m aiming to have it all completed by the end of February.

      Adam

  4. Ken says:

    I’m not fond of your recent change with format of calendar and pipeline dates. It’s very, very difficult to follow test completion and test result dates.

    Also, why is there pre 2013 data shown on pages? Is this just for a historical record? This makes things all the more confusing.

    Thanks, Ken

    • admin says:

      Hi Ken,

      Thanks for your feedback.

      I am presuming you are referring to the “Primary/Completion Date” column. Is this correct? These dates are provided by clinicaltrials.gov but yes, they often differ from company guidance, which provides some confusion. A decision has already been made to remove this column and the “Clinical trials ID” column. This will occur later this year or in January.

      Could you clarify what you meant by “calendar AND pipeline dates”? Are you also referring to the FDA Calendar?

      In regard to your second question, yes, all the data shown in the pipeline database is “historical” and many of my readers have mentioned they would like a reference point to previous trials. Could you clarify where the confusion arises?

      The latest trial information should be listed in the database. If a company is undergoing Phase 3 trials and there are Phase 2 data in the database, then this is an error. On the other hand, if a company has released data in, say 2012, and there haven’t been any further updates, then the 2012 entry should be the most recent entry in the database.

  5. Ken says:

    My humble apologies. I managed to lose track of the FDA Calendar link and started viewing your Company Pipeline database. (I think because the fda calendar is retrieved by clicking on the toolbar and not clicking on its dropdown menu items.)

    Nonetheless, the problem arose when I noticed that the Company Pipeline data appears not as complete, comprehensive, and forward looking as the FDA calendar data I had observed earlier.

    Now that things are working again on my end…

    Thank you for your remarkable website.

    -Ken

    • admin says:

      Thanks Ken,

      Actually, I appreciate your comments there as I’m sure you’re not the only person who has missed the FDA Calendar because it doesn’t appear in the dropdown menu.

      I’ve made a slight change so that you can now access the FDA Calendar by either clicking on the toolbar or through the dropdown menu.

      Thanks,

      Adam

  6. Anat says:

    Hi,

    Thanks for the great work!

    You have one mistake in CBRX, which needs to be removed (it’s about CPRX).

  7. zeng says:

    the interim data of BDSI’s PDN trial(phas 3)was expected in 3Q,2014,not the end of 2014.
    “We are very pleased with the rapid progression of this study, which we expect will allow for an independent interim analysis based on 50% of the patients completed during the third quarter of this year – one quarter ahead of schedule,” Based on the enrollment of this trial, and assuming no additional patients will be required following the interim analysis, we should have top-line study results by the end of the year.

Leave a Reply